

WEBVTT

NOTE duration:"00:57:58.3360000"

NOTE language:en-us

NOTE Confidence: 0.80177414

00:00:00.000 --> 00:00:03.465 Substituting today very happy to be here.

NOTE Confidence: 0.80177414

00:00:03.470 --> 00:00:06.449 So we have two talks today and I think

NOTE Confidence: 0.80177414

00:00:06.449 --> 00:00:09.605 it should be a very interesting hour.

NOTE Confidence: 0.80177414

00:00:09.610 --> 00:00:13.075 Our first talk will be by Anne Chang and

NOTE Confidence: 0.80177414

00:00:13.075 --> 00:00:16.134 actually ends very much in the news today.

NOTE Confidence: 0.80177414

00:00:16.140 --> 00:00:16.524 Congratulations.

NOTE Confidence: 0.80177414

00:00:16.524 --> 00:00:19.596 And so an is associate Professor of Medicine,

NOTE Confidence: 0.80177414

00:00:19.600 --> 00:00:21.892 medical oncology and Deputy Chief medical

NOTE Confidence: 0.80177414

00:00:21.892 --> 00:00:23.855 Officer and Chief Integration Officer

NOTE Confidence: 0.80177414

00:00:23.855 --> 00:00:25.740 Officer for Smile Cancer hospital.

NOTE Confidence: 0.80177414

00:00:25.740 --> 00:00:29.136 As of about 3 hours ago.

NOTE Confidence: 0.80177414

00:00:29.140 --> 00:00:30.532 She specializes in thoracic

NOTE Confidence: 0.80177414

00:00:30.532 --> 00:00:32.272 oncology with a background in

NOTE Confidence: 0.80177414

00:00:32.272 --> 00:00:33.849 translational research and metastases,

NOTE Confidence: 0.80177414

00:00:33.850 --> 00:00:35.789 and a clinical focus has been built

NOTE Confidence: 0.80177414

00:00:35.789 --> 00:00:38.019 has been to build an amazing small

NOTE Confidence: 0.80177414

00:00:38.019 --> 00:00:40.568 cell lung cancer program here with a

NOTE Confidence: 0.80177414

00:00:40.568 --> 00:00:42.452 comprehensive portfolio of clinical

NOTE Confidence: 0.80177414

00:00:42.452 --> 00:00:44.336 trials testing novel therapeutics.

NOTE Confidence: 0.80177414

00:00:44.340 --> 00:00:46.476 Her research interests focus on focus

NOTE Confidence: 0.80177414

00:00:46.476 --> 00:00:48.726 and development of clinical trials and

NOTE Confidence: 0.80177414

00:00:48.726 --> 00:00:50.641 translational studies to test novel

NOTE Confidence: 0.80177414

00:00:50.641 --> 00:00:52.522 agents and combinations with immune

NOTE Confidence: 0.80177414

00:00:52.522 --> 00:00:54.192 checkpoint inhibitors for both small

NOTE Confidence: 0.80177414

00:00:54.192 --> 00:00:57.908 cell and non small cell lung tumors.

NOTE Confidence: 0.80177414

00:00:57.910 --> 00:01:00.136 Over now nine years an she's helped

NOTE Confidence: 0.80177414

00:01:00.136 --> 00:01:02.219 to build our smiling network,

NOTE Confidence: 0.80177414

00:01:02.220 --> 00:01:04.509 which I think will hear about today

NOTE Confidence: 0.80177414

00:01:04.509 --> 00:01:05.958 and overseas operations quality

NOTE Confidence: 0.80177414

00:01:05.958 --> 00:01:07.598 efforts in clinical research,
NOTE Confidence: 0.80177414

00:01:07.600 --> 00:01:08.731 adult care centers.
NOTE Confidence: 0.80177414

00:01:08.731 --> 00:01:10.993 She's a particular focus in quality
NOTE Confidence: 0.80177414

00:01:10.993 --> 00:01:12.496 measurement and improvement and
NOTE Confidence: 0.80177414

00:01:12.496 --> 00:01:14.626 his work to achieve ASCO copy
NOTE Confidence: 0.80177414

00:01:14.626 --> 00:01:16.217 certification for the entire smell.
NOTE Confidence: 0.80177414

00:01:16.220 --> 00:01:17.294 Academic clinical practice
NOTE Confidence: 0.80177414

00:01:17.294 --> 00:01:18.368 of actually received.
NOTE Confidence: 0.80177414

00:01:18.370 --> 00:01:20.170 Actually, the Joe Simone Award,
NOTE Confidence: 0.80177414

00:01:20.170 --> 00:01:22.676 just recently in Q just passed away
NOTE Confidence: 0.80177414

00:01:22.676 --> 00:01:25.548 last week, but a big honor for Masco,
NOTE Confidence: 0.80177414

00:01:25.550 --> 00:01:27.944 so an it's a pleasure to have
NOTE Confidence: 0.80177414

00:01:27.944 --> 00:01:30.278 you here for our first talk.
NOTE Confidence: 0.80177414

00:01:30.280 --> 00:01:32.192 Transformation in quality building
NOTE Confidence: 0.80177414

00:01:32.192 --> 00:01:33.626 a cancer network,
NOTE Confidence: 0.80177414

00:01:33.630 --> 00:01:34.100 and.

NOTE Confidence: 0.8790028

00:01:35.280 --> 00:01:37.476 Thanks Roy, it's really a pleasure

NOTE Confidence: 0.8790028

00:01:37.476 --> 00:01:40.651 to be able to talk to you today

NOTE Confidence: 0.8790028

00:01:40.651 --> 00:01:42.686 and thanks for the invitation.

NOTE Confidence: 0.8790028

00:01:42.690 --> 00:01:44.868 I was trying to decide between

NOTE Confidence: 0.8790028

00:01:44.868 --> 00:01:46.980 lung cancer and the network,

NOTE Confidence: 0.8790028

00:01:46.980 --> 00:01:49.906 but because of the timing of the

NOTE Confidence: 0.8790028

00:01:49.906 --> 00:01:51.933 announcement this morning and I

NOTE Confidence: 0.8790028

00:01:51.933 --> 00:01:54.355 thought that it would be nice to

NOTE Confidence: 0.8790028

00:01:54.355 --> 00:01:56.730 highlight the work that has gone

NOTE Confidence: 0.8790028

00:01:56.730 --> 00:01:58.680 into building a cancer network.

NOTE Confidence: 0.8790028

00:01:58.680 --> 00:02:00.630 So that's what I'm focusing,

NOTE Confidence: 0.8790028

00:02:00.630 --> 00:02:03.290 but I did put in a couple

NOTE Confidence: 0.8790028

00:02:03.290 --> 00:02:05.758 of slides with my trials so.

NOTE Confidence: 0.8790028

00:02:05.760 --> 00:02:08.488 I suck that in.

NOTE Confidence: 0.8790028

00:02:08.490 --> 00:02:13.834 OK, so I'm sharing my screen my disclosures.

NOTE Confidence: 0.8790028

00:02:13.840 --> 00:02:15.570 And this is for four.
NOTE Confidence: 0.8790028

00:02:15.570 --> 00:02:16.949 If you recognize it,
NOTE Confidence: 0.8790028

00:02:16.950 --> 00:02:18.705 it's South Ferry terminal farmers
NOTE Confidence: 0.8790028

00:02:18.705 --> 00:02:21.147 market in San Francisco and it's amazing
NOTE Confidence: 0.8790028

00:02:21.147 --> 00:02:23.324 place because the quality of the food
NOTE Confidence: 0.8790028

00:02:23.324 --> 00:02:25.597 and the shops are really outstanding.
NOTE Confidence: 0.8790028

00:02:25.600 --> 00:02:27.586 I had the best Peach I've
NOTE Confidence: 0.8790028

00:02:27.586 --> 00:02:29.410 ever had in my life.
NOTE Confidence: 0.8790028

00:02:29.410 --> 00:02:30.995 The atmosphere is buzzing in
NOTE Confidence: 0.8790028

00:02:30.995 --> 00:02:33.220 the shops are full of colorful,
NOTE Confidence: 0.8790028

00:02:33.220 --> 00:02:35.434 beautiful produce as far as you
NOTE Confidence: 0.8790028

00:02:35.434 --> 00:02:38.340 can see and when I was here which
NOTE Confidence: 0.8790028

00:02:38.340 --> 00:02:40.763 was pre covid the last time it
NOTE Confidence: 0.8790028

00:02:40.763 --> 00:02:42.968 seemed to me that this was more
NOTE Confidence: 0.8790028

00:02:42.968 --> 00:02:44.944 than a farmers market where.
NOTE Confidence: 0.8790028

00:02:44.944 --> 00:02:47.632 Each farmer sets up their shop

NOTE Confidence: 0.8790028
00:02:47.632 --> 00:02:49.458 individually next to each other,
NOTE Confidence: 0.8790028
00:02:49.460 --> 00:02:51.818 but somehow there was a transformation
NOTE Confidence: 0.8790028
00:02:51.818 --> 00:02:53.892 of the individual stands into
NOTE Confidence: 0.8790028
00:02:53.892 --> 00:02:55.640 a different collective entity,
NOTE Confidence: 0.8790028
00:02:55.640 --> 00:02:56.464 real community,
NOTE Confidence: 0.8790028
00:02:56.464 --> 00:02:59.760 and so in the same way that in
NOTE Confidence: 0.8790028
00:02:59.760 --> 00:03:02.592 the same way I want to talk about
NOTE Confidence: 0.8790028
00:03:02.592 --> 00:03:05.119 cancer or cancer network today,
NOTE Confidence: 0.8790028
00:03:05.120 --> 00:03:07.190 there really has been a trend
NOTE Confidence: 0.8790028
00:03:07.190 --> 00:03:10.186 over the past 10 years of academic
NOTE Confidence: 0.8790028
00:03:10.186 --> 00:03:12.741 institutions or other entities buying
NOTE Confidence: 0.8790028
00:03:12.741 --> 00:03:16.018 up practices or putting up their names on.
NOTE Confidence: 0.8790028
00:03:16.020 --> 00:03:16.802 Affiliated practices,
NOTE Confidence: 0.8790028
00:03:16.802 --> 00:03:19.930 but what I wanted to focus on is
NOTE Confidence: 0.8790028
00:03:20.003 --> 00:03:22.635 how to how I think we've built
NOTE Confidence: 0.8790028

00:03:22.635 --> 00:03:24.420 a real transformative network,
NOTE Confidence: 0.8790028

00:03:24.420 --> 00:03:26.826 a community that is better than
NOTE Confidence: 0.8790028

00:03:26.826 --> 00:03:29.035 the individual units where cancer
NOTE Confidence: 0.8790028

00:03:29.035 --> 00:03:31.685 delivery is really somehow transformed.
NOTE Confidence: 0.8790028

00:03:31.690 --> 00:03:34.108 And so you know, this is,
NOTE Confidence: 0.8790028

00:03:34.110 --> 00:03:36.630 let's go to transformation theory too
NOTE Confidence: 0.8790028

00:03:36.630 --> 00:03:39.369 as a guiding principle for this work.
NOTE Confidence: 0.8790028

00:03:39.370 --> 00:03:40.579 As it is,
NOTE Confidence: 0.8790028

00:03:40.579 --> 00:03:42.997 Carter said transformation is a process,
NOTE Confidence: 0.8790028

00:03:43.000 --> 00:03:44.032 not an event.
NOTE Confidence: 0.8790028

00:03:44.032 --> 00:03:46.440 And you start with a sense of
NOTE Confidence: 0.8790028

00:03:46.524 --> 00:03:49.116 urgency form a coalition and you
NOTE Confidence: 0.8790028

00:03:49.116 --> 00:03:51.490 create and share that vision.
NOTE Confidence: 0.8790028

00:03:51.490 --> 00:03:54.714 You empower others to act on that vision.
NOTE Confidence: 0.8790028

00:03:54.720 --> 00:03:57.138 You plan, create short term wins,
NOTE Confidence: 0.8790028

00:03:57.140 --> 00:03:58.352 consolidate those advances,

NOTE Confidence: 0.8790028

00:03:58.352 --> 00:03:59.968 and hardwire new systems.

NOTE Confidence: 0.8790028

00:03:59.970 --> 00:04:02.490 And I think the bottom line.

NOTE Confidence: 0.8790028

00:04:02.490 --> 00:04:04.860 Here is that quality improvement

NOTE Confidence: 0.8790028

00:04:04.860 --> 00:04:07.645 methodology is really been the basis

NOTE Confidence: 0.8790028

00:04:07.645 --> 00:04:10.349 of my job in the network and formed

NOTE Confidence: 0.8790028

00:04:10.349 --> 00:04:12.915 the foundation of building our vision

NOTE Confidence: 0.8790028

00:04:12.915 --> 00:04:15.456 over the past almost 10 years.

NOTE Confidence: 0.8790028

00:04:15.456 --> 00:04:17.832 So the objectives for today's talk

NOTE Confidence: 0.8790028

00:04:17.832 --> 00:04:20.510 really are two number one provider,

NOTE Confidence: 0.8790028

00:04:20.510 --> 00:04:21.926 network development, overview,

NOTE Confidence: 0.8790028

00:04:21.926 --> 00:04:23.814 describe quality concepts and

NOTE Confidence: 0.8790028

00:04:23.814 --> 00:04:25.663 metrics and network development

NOTE Confidence: 0.8790028

00:04:25.663 --> 00:04:27.859 to discuss ways to further the

NOTE Confidence: 0.8790028

00:04:27.859 --> 00:04:29.729 research mission in the network.

NOTE Confidence: 0.8790028

00:04:29.730 --> 00:04:32.350 And then finally recognize the

NOTE Confidence: 0.8790028

00:04:32.350 --> 00:04:34.446 benefits of expanded community.
NOTE Confidence: 0.8790028

00:04:34.450 --> 00:04:38.118 So this is how it all began.
NOTE Confidence: 0.8790028

00:04:38.120 --> 00:04:42.520 We we when I started my job this was in 2011.
NOTE Confidence: 0.8790028

00:04:42.520 --> 00:04:44.056 There was no network.
NOTE Confidence: 0.8790028

00:04:44.056 --> 00:04:47.256 We had hired anybody but we did have
NOTE Confidence: 0.8790028

00:04:47.256 --> 00:04:50.512 Yale Smilow state of the art disease based,
NOTE Confidence: 0.8790028

00:04:50.520 --> 00:04:52.120 patient centered clinical operation.
NOTE Confidence: 0.8790028

00:04:52.120 --> 00:04:53.720 We had outstanding faculty,
NOTE Confidence: 0.8790028

00:04:53.720 --> 00:04:54.194 staff,
NOTE Confidence: 0.8790028

00:04:54.194 --> 00:04:54.668 trainees,
NOTE Confidence: 0.8790028

00:04:54.668 --> 00:04:56.564 cutting edge clinical research
NOTE Confidence: 0.8790028

00:04:56.564 --> 00:04:58.460 resources and across organizational
NOTE Confidence: 0.8790028

00:04:58.520 --> 00:05:00.375 commitment for expansion and really
NOTE Confidence: 0.8790028

00:05:00.375 --> 00:05:02.230 a powerful coalition of folks
NOTE Confidence: 0.8576237

00:05:02.291 --> 00:05:03.716 to carry out that vision,
NOTE Confidence: 0.8576237

00:05:03.720 --> 00:05:05.755 which was really to provide

NOTE Confidence: 0.8576237

00:05:05.755 --> 00:05:07.790 comprehensive care to all patients.

NOTE Confidence: 0.8576237

00:05:07.790 --> 00:05:10.569 Close to home in Connecticut and to

NOTE Confidence: 0.8576237

00:05:10.569 --> 00:05:13.182 provide a platform for Yale Clinical

NOTE Confidence: 0.8576237

00:05:13.182 --> 00:05:15.876 Research and expand access to trials.

NOTE Confidence: 0.8576237

00:05:15.880 --> 00:05:18.538 So this is really the result.

NOTE Confidence: 0.8576237

00:05:18.540 --> 00:05:21.210 9 1/2 years later the this.

NOTE Confidence: 0.8576237

00:05:21.210 --> 00:05:23.778 This is our clinical footprint in

NOTE Confidence: 0.8576237

00:05:23.778 --> 00:05:26.090 Connecticut and in Rhode Island.

NOTE Confidence: 0.8576237

00:05:26.090 --> 00:05:29.482 This stars are where our our care centers

NOTE Confidence: 0.8576237

00:05:29.482 --> 00:05:33.062 are and we do provide care to patients

NOTE Confidence: 0.8576237

00:05:33.062 --> 00:05:36.299 within 30 minutes of where they live.

NOTE Confidence: 0.8576237

00:05:36.300 --> 00:05:37.190 In Connecticut.

NOTE Confidence: 0.8576237

00:05:37.190 --> 00:05:40.325 We provide care to about 45% of

NOTE Confidence: 0.8576237

00:05:40.325 --> 00:05:42.650 newly diagnosed cancer patients in

NOTE Confidence: 0.8576237

00:05:42.650 --> 00:05:45.888 Connecticut and we also provide about or.

NOTE Confidence: 0.8576237

00:05:45.890 --> 00:05:49.271 We accrue about 25% of of therapeutic

NOTE Confidence: 0.8576237

00:05:49.271 --> 00:05:51.030 clinical trial enrollments as,

NOTE Confidence: 0.8576237

00:05:51.030 --> 00:05:52.500 as Roy mentioned,

NOTE Confidence: 0.8576237

00:05:52.500 --> 00:05:54.950 we have achieved ASCO quality

NOTE Confidence: 0.8576237

00:05:54.950 --> 00:05:56.856 oncology certification throughout our

NOTE Confidence: 0.8576237

00:05:56.856 --> 00:05:59.424 entire network in the main campus.

NOTE Confidence: 0.8576237

00:05:59.430 --> 00:06:00.531 This is away.

NOTE Confidence: 0.8576237

00:06:00.531 --> 00:06:03.100 This is actually the only way to

NOTE Confidence: 0.8576237

00:06:03.184 --> 00:06:05.500 certify ambulatory practices.

NOTE Confidence: 0.8576237

00:06:05.500 --> 00:06:09.703 Many of you are familiar with the AC OS,

NOTE Confidence: 0.8576237

00:06:09.710 --> 00:06:13.218 which certifies cancer programs.

NOTE Confidence: 0.8576237

00:06:13.220 --> 00:06:18.276 In all of the physicians are what YM?

NOTE Confidence: 0.8576237

00:06:18.280 --> 00:06:20.570 With the exception of Hartford,

NOTE Confidence: 0.8576237

00:06:20.570 --> 00:06:22.850 where the physicians are still

NOTE Confidence: 0.8576237

00:06:22.850 --> 00:06:24.218 Saint Francis employed,

NOTE Confidence: 0.8576237

00:06:24.220 --> 00:06:27.461 but do have a faculty appointments and

NOTE Confidence: 0.8576237

00:06:27.461 --> 00:06:30.986 are a stipend from from Yale and all

NOTE Confidence: 0.8576237

00:06:30.986 --> 00:06:34.729 of the staff are smilow employed or least,

NOTE Confidence: 0.8576237

00:06:34.730 --> 00:06:38.447 and we do have cross system policies

NOTE Confidence: 0.8576237

00:06:38.447 --> 00:06:42.080 and procedures and quality initiatives.

NOTE Confidence: 0.8576237

00:06:42.080 --> 00:06:44.328 This is a timeline where I started

NOTE Confidence: 0.8576237

00:06:44.328 --> 00:06:47.495 here in in in 2011 and and we did

NOTE Confidence: 0.8576237

00:06:47.495 --> 00:06:50.316 not have a network and then over

NOTE Confidence: 0.8576237

00:06:50.316 --> 00:06:53.269 the course of the next 9 1/2 years.

NOTE Confidence: 0.8576237

00:06:53.270 --> 00:06:56.406 We we brought in a practices and

NOTE Confidence: 0.8576237

00:06:56.406 --> 00:06:58.610 in in the in the.

NOTE Confidence: 0.8576237

00:06:58.610 --> 00:07:03.634 In doing so really had the opportunity to.

NOTE Confidence: 0.8576237

00:07:03.640 --> 00:07:06.238 Have multiple PDF a cycles in

NOTE Confidence: 0.8576237

00:07:06.238 --> 00:07:09.152 terms of improving our process and

NOTE Confidence: 0.8576237

00:07:09.152 --> 00:07:11.897 improving our in perfecting our

NOTE Confidence: 0.8576237

00:07:11.897 --> 00:07:14.999 onboarding process and now as I said

NOTE Confidence: 0.8576237

00:07:14.999 --> 00:07:17.496 we have 15 locations in two states.
NOTE Confidence: 0.8576237

00:07:17.496 --> 00:07:21.064 We have all we have almost 50 MD's,
NOTE Confidence: 0.8576237

00:07:21.070 --> 00:07:23.790 16 aips and over 400 staff we see
NOTE Confidence: 0.8576237

00:07:23.790 --> 00:07:26.413 over 9000 new patients 100 and
NOTE Confidence: 0.8576237

00:07:26.413 --> 00:07:28.743 25,000 treatment visits yearly and
NOTE Confidence: 0.8576237

00:07:28.743 --> 00:07:31.938 the contribution margin on an annual
NOTE Confidence: 0.8576237

00:07:31.938 --> 00:07:34.583 basis is greater than 110,000,000.
NOTE Confidence: 0.8576237

00:07:34.590 --> 00:07:38.054 So I think that this is really been
NOTE Confidence: 0.8576237

00:07:38.054 --> 00:07:40.962 successful and I'm going to talk a
NOTE Confidence: 0.8576237

00:07:40.962 --> 00:07:43.494 little bit about the onboarding practice
NOTE Confidence: 0.8576237

00:07:43.494 --> 00:07:46.710 the onboarding process first, so.
NOTE Confidence: 0.8576237

00:07:46.710 --> 00:07:49.434 This is where we really utilized
NOTE Confidence: 0.8576237

00:07:49.434 --> 00:07:51.250 integration and transformative change
NOTE Confidence: 0.8576237

00:07:51.315 --> 00:07:53.780 strategies to engage the stakeholders.
NOTE Confidence: 0.8576237

00:07:53.780 --> 00:07:56.130 The physicians that the staff
NOTE Confidence: 0.8576237

00:07:56.130 --> 00:07:58.420 in the practice, and we.

NOTE Confidence: 0.8576237

00:07:58.420 --> 00:08:01.500 There's at the bottom line is that

NOTE Confidence: 0.8576237

00:08:01.500 --> 00:08:04.140 there's really no shortcut here.

NOTE Confidence: 0.8576237

00:08:04.140 --> 00:08:06.960 It really is hard work having

NOTE Confidence: 0.8576237

00:08:06.960 --> 00:08:08.840 regular meetings on transition

NOTE Confidence: 0.8576237

00:08:08.925 --> 00:08:11.200 issues such as epic pharmacy,

NOTE Confidence: 0.8576237

00:08:11.200 --> 00:08:12.346 workflow changes,

NOTE Confidence: 0.8576237

00:08:12.346 --> 00:08:15.211 and those transitioned into practice

NOTE Confidence: 0.8576237

00:08:15.211 --> 00:08:17.940 meetings which were very useful.

NOTE Confidence: 0.8576237

00:08:17.940 --> 00:08:21.918 On an ongoing are useful on an ongoing basis.

NOTE Confidence: 0.8576237

00:08:21.920 --> 00:08:24.566 We developed a formal onboarding curriculum,

NOTE Confidence: 0.8576237

00:08:24.570 --> 00:08:26.910 and this utilized leaders and peers

NOTE Confidence: 0.8576237

00:08:26.910 --> 00:08:29.554 is faculty and it really included

NOTE Confidence: 0.8576237

00:08:29.554 --> 00:08:32.074 the Smilow vision and structure.

NOTE Confidence: 0.8576237

00:08:32.080 --> 00:08:33.968 Faculty roles and expectations.

NOTE Confidence: 0.8576237

00:08:33.968 --> 00:08:38.021 What does it mean now to be part of

NOTE Confidence: 0.8576237

00:08:38.021 --> 00:08:40.928 Yale and Smilow? How does quality work?
NOTE Confidence: 0.8576237

00:08:40.928 --> 00:08:43.580 How does the research apparatus work?
NOTE Confidence: 0.8576237

00:08:43.580 --> 00:08:45.790 Who are the dart leaders?
NOTE Confidence: 0.8576237

00:08:45.790 --> 00:08:48.210 What is that mean?
NOTE Confidence: 0.8576237

00:08:48.210 --> 00:08:52.889 What is what are academic mentors and and?
NOTE Confidence: 0.8576237

00:08:52.890 --> 00:08:55.644 So going through that that curriculum
NOTE Confidence: 0.8576237

00:08:55.644 --> 00:08:57.480 also involving team building
NOTE Confidence: 0.8165863

00:08:57.551 --> 00:08:59.663 and leadership training and
NOTE Confidence: 0.8165863

00:08:59.663 --> 00:09:01.247 including our multidisciplinary
NOTE Confidence: 0.8165863

00:09:01.247 --> 00:09:04.020 members not only met Aachen Heme,
NOTE Confidence: 0.8165863

00:09:04.020 --> 00:09:08.115 but our surgical colleagues are rat out
NOTE Confidence: 0.8165863

00:09:08.115 --> 00:09:11.858 colleagues pain and palliative care so.
NOTE Confidence: 0.8165863

00:09:11.860 --> 00:09:16.488 Um? Be the next.
NOTE Confidence: 0.8165863

00:09:16.490 --> 00:09:18.842 Either or the next part of quality
NOTE Confidence: 0.8165863

00:09:18.842 --> 00:09:20.640 improvement is really measurement,
NOTE Confidence: 0.8165863

00:09:20.640 --> 00:09:24.024 and this is a graphic of the really PDS.

NOTE Confidence: 0.8165863

00:09:24.030 --> 00:09:25.920 A cycle you have multiple.

NOTE Confidence: 0.8692515

00:09:28.260 --> 00:09:29.872 You know, iterations of

NOTE Confidence: 0.8692515

00:09:29.872 --> 00:09:31.887 how do you improve care,

NOTE Confidence: 0.8692515

00:09:31.890 --> 00:09:33.900 but measurement is really important,

NOTE Confidence: 0.8692515

00:09:33.900 --> 00:09:36.833 and so we started measuring at baseline

NOTE Confidence: 0.8692515

00:09:36.833 --> 00:09:40.047 because we wanted to make sure that we

NOTE Confidence: 0.8692515

00:09:40.047 --> 00:09:42.370 could measure progress and not just,

NOTE Confidence: 0.8692515

00:09:42.370 --> 00:09:45.586 you know, stick a sign on the door.

NOTE Confidence: 0.8692515

00:09:45.590 --> 00:09:48.033 That said, Yale Smilow and this paper

NOTE Confidence: 0.8692515

00:09:48.033 --> 00:09:50.073 published in 2018 really showed

NOTE Confidence: 0.8692515

00:09:50.073 --> 00:09:52.839 improvements in multiple domains of quality,

NOTE Confidence: 0.8692515

00:09:52.840 --> 00:09:54.452 including volume, clinical integration,

NOTE Confidence: 0.8692515

00:09:54.452 --> 00:09:56.583 quality metrics, and patient satisfaction.

NOTE Confidence: 0.8692515

00:09:56.583 --> 00:10:00.050 I'm going to show you. Few of those.

NOTE Confidence: 0.8692515

00:10:00.050 --> 00:10:02.570 At some of that data now.

NOTE Confidence: 0.8692515

00:10:02.570 --> 00:10:05.120 So in annual visits for chemo
NOTE Confidence: 0.8692515

00:10:05.120 --> 00:10:08.243 this you can see the main campus
NOTE Confidence: 0.8692515

00:10:08.243 --> 00:10:11.344 in blue over the years and then.
NOTE Confidence: 0.8692515

00:10:11.350 --> 00:10:13.140 When the Kirsten's Care Center
NOTE Confidence: 0.8692515

00:10:13.140 --> 00:10:14.572 started in in 2012,
NOTE Confidence: 0.8692515

00:10:14.580 --> 00:10:17.429 you could see the growth has really
NOTE Confidence: 0.8692515

00:10:17.429 --> 00:10:19.709 been significant and we do give
NOTE Confidence: 0.8692515

00:10:19.709 --> 00:10:21.998 now more chemo in our care centers
NOTE Confidence: 0.8692515

00:10:22.075 --> 00:10:24.037 closer to home for our patients
NOTE Confidence: 0.8692515

00:10:24.037 --> 00:10:28.398 than we do in the main campus.
NOTE Confidence: 0.8692515

00:10:28.400 --> 00:10:30.392 In terms of standardization,
NOTE Confidence: 0.8692515

00:10:30.392 --> 00:10:31.886 we utilized coping.
NOTE Confidence: 0.8692515

00:10:31.890 --> 00:10:35.454 Measurement Copy is a program through
NOTE Confidence: 0.8692515

00:10:35.454 --> 00:10:38.505 ASCO called quality Oncology Practice
NOTE Confidence: 0.8692515

00:10:38.505 --> 00:10:41.430 Initiative and it consists of.
NOTE Confidence: 0.8692515

00:10:41.430 --> 00:10:45.110 Go up to 90 metrics of of oncology

NOTE Confidence: 0.8692515

00:10:45.110 --> 00:10:46.990 of ambulatory oncology,

NOTE Confidence: 0.8692515

00:10:46.990 --> 00:10:49.415 quality that have been developed

NOTE Confidence: 0.8692515

00:10:49.415 --> 00:10:51.355 national iyanar consensus based

NOTE Confidence: 0.8692515

00:10:51.355 --> 00:10:54.058 and evidence based when available,

NOTE Confidence: 0.8692515

00:10:54.060 --> 00:10:59.030 so we had a measurement at baseline.

NOTE Confidence: 0.8692515

00:10:59.030 --> 00:11:00.970 Representing the practices before they

NOTE Confidence: 0.8692515

00:11:00.970 --> 00:11:03.743 joined and then this is four years

NOTE Confidence: 0.8692515

00:11:03.743 --> 00:11:06.035 later we looked at the significant

NOTE Confidence: 0.8692515

00:11:06.035 --> 00:11:08.217 differences and saw that really the

NOTE Confidence: 0.8692515

00:11:08.217 --> 00:11:10.245 only changes were in the positive.

NOTE Confidence: 0.8692515

00:11:10.250 --> 00:11:12.847 These are actually shown here and and

NOTE Confidence: 0.8692515

00:11:12.847 --> 00:11:15.617 so this was really important to me

NOTE Confidence: 0.8692515

00:11:15.617 --> 00:11:18.400 because I wanted to make sure again

NOTE Confidence: 0.8692515

00:11:18.400 --> 00:11:22.114 it wasn't just putting in a sign on the door,

NOTE Confidence: 0.8692515

00:11:22.114 --> 00:11:25.978 but that we were actually using.

NOTE Confidence: 0.8692515

00:11:25.980 --> 00:11:28.172 National consensus based metrics
NOTE Confidence: 0.8692515

00:11:28.172 --> 00:11:31.460 to show that we were improving
NOTE Confidence: 0.8692515

00:11:31.553 --> 00:11:33.729 quality for our patients.
NOTE Confidence: 0.8692515

00:11:33.730 --> 00:11:34.570 We also,
NOTE Confidence: 0.8692515

00:11:34.570 --> 00:11:37.090 as Roy mentioned at the beginning,
NOTE Confidence: 0.8692515

00:11:37.090 --> 00:11:39.190 did copy certification across our
NOTE Confidence: 0.8692515

00:11:39.190 --> 00:11:41.290 network and the academic campus.
NOTE Confidence: 0.8692515

00:11:41.290 --> 00:11:43.810 This is similar to the ACOs
NOTE Confidence: 0.8692515

00:11:43.810 --> 00:11:44.650 certification there.
NOTE Confidence: 0.8692515

00:11:44.650 --> 00:11:47.611 26 standards and you really have to
NOTE Confidence: 0.8692515

00:11:47.611 --> 00:11:50.557 show in document that the process
NOTE Confidence: 0.8692515

00:11:50.557 --> 00:11:53.731 from soup to nuts of chemotherapy
NOTE Confidence: 0.8692515

00:11:53.731 --> 00:11:55.669 administration and policies and
NOTE Confidence: 0.8692515

00:11:55.669 --> 00:11:58.749 procedures are in place that show us.
NOTE Confidence: 0.8692515

00:11:58.750 --> 00:12:01.347 That are up to snuff for ASCO
NOTE Confidence: 0.8692515

00:12:01.347 --> 00:12:04.100 certification and we re certified in 2019.

NOTE Confidence: 0.80547464

00:12:06.640 --> 00:12:09.040 Um, regarding clinical integration.

NOTE Confidence: 0.80547464

00:12:09.040 --> 00:12:12.040 I'll just show you the.

NOTE Confidence: 0.80547464

00:12:12.040 --> 00:12:13.800 And this represents cases

NOTE Confidence: 0.80547464

00:12:13.800 --> 00:12:15.560 President care Center cases

NOTE Confidence: 0.80547464

00:12:15.560 --> 00:12:17.839 presented at smilow tumor boards.

NOTE Confidence: 0.80547464

00:12:17.840 --> 00:12:20.414 We have 13 disease specific multi

NOTE Confidence: 0.80547464

00:12:20.414 --> 00:12:23.480 D tumor boards and we've asked all

NOTE Confidence: 0.80547464

00:12:23.480 --> 00:12:26.006 of our physicians to present one

NOTE Confidence: 0.80547464

00:12:26.006 --> 00:12:28.862 to two cases a month understanding

NOTE Confidence: 0.80547464

00:12:28.862 --> 00:12:32.136 that we can't present all of them.

NOTE Confidence: 0.80547464

00:12:32.136 --> 00:12:34.884 But really, those complex cases that

NOTE Confidence: 0.80547464

00:12:34.884 --> 00:12:38.438 need that multi D discussion needs to be

NOTE Confidence: 0.80547464

00:12:38.438 --> 00:12:41.947 presented and so you can see in 2013.

NOTE Confidence: 0.80547464

00:12:41.947 --> 00:12:44.282 This was difficult because the

NOTE Confidence: 0.80547464

00:12:44.282 --> 00:12:46.150 logistics around dialing in,

NOTE Confidence: 0.80547464

00:12:46.150 --> 00:12:49.494 which is so easy now by assume it.
NOTE Confidence: 0.80547464

00:12:49.500 --> 00:12:52.440 But at that time was very difficult.
NOTE Confidence: 0.80547464

00:12:52.440 --> 00:12:55.860 Getting the path reviewed, getting the.
NOTE Confidence: 0.80547464

00:12:55.860 --> 00:12:58.305 Radiology diagnostic imaging to be
NOTE Confidence: 0.80547464

00:12:58.305 --> 00:13:01.555 available that was really hard at the
NOTE Confidence: 0.80547464

00:13:01.555 --> 00:13:04.082 time and now I think we've received
NOTE Confidence: 0.80547464

00:13:04.082 --> 00:13:06.858 we've we've sort of the steady state,
NOTE Confidence: 0.80547464

00:13:06.860 --> 00:13:08.548 is right around 500.
NOTE Confidence: 0.80547464

00:13:08.548 --> 00:13:10.236 That's the case also.
NOTE Confidence: 0.80547464

00:13:10.240 --> 00:13:12.360 Sorry, this is 2018-2019, 2020,
NOTE Confidence: 0.80547464

00:13:12.360 --> 00:13:14.470 right around the 500 mark,
NOTE Confidence: 0.80547464

00:13:14.470 --> 00:13:17.640 which I think represents sort
NOTE Confidence: 0.80547464

00:13:17.640 --> 00:13:20.176 of the steady state.
NOTE Confidence: 0.80547464

00:13:20.180 --> 00:13:22.700 Um, with respect to customer service.
NOTE Confidence: 0.80547464

00:13:22.700 --> 00:13:26.330 Those of you who have.
NOTE Confidence: 0.80547464

00:13:26.330 --> 00:13:27.084 You know,

NOTE Confidence: 0.80547464

00:13:27.084 --> 00:13:29.723 pay attention to press ganey know that

NOTE Confidence: 0.80547464

00:13:29.723 --> 00:13:32.538 we always cluster in this 90s area.

NOTE Confidence: 0.80547464

00:13:32.540 --> 00:13:35.636 It's very difficult to make any changes here,

NOTE Confidence: 0.80547464

00:13:35.640 --> 00:13:38.216 but if you look at again baseline

NOTE Confidence: 0.80547464

00:13:38.216 --> 00:13:40.599 press ganey scores for practices that

NOTE Confidence: 0.80547464

00:13:40.599 --> 00:13:43.005 we acquired and six years later,

NOTE Confidence: 0.80547464

00:13:43.010 --> 00:13:45.618 you can see that in all of the

NOTE Confidence: 0.80547464

00:13:45.618 --> 00:13:48.450 cases we actually stayed the same.

NOTE Confidence: 0.80547464

00:13:48.450 --> 00:13:50.430 We're actually improved with one

NOTE Confidence: 0.80547464

00:13:50.430 --> 00:13:53.099 exception here is is this the site,

NOTE Confidence: 0.80547464

00:13:53.100 --> 00:13:55.422 but in some cases really significantly

NOTE Confidence: 0.80547464

00:13:55.422 --> 00:13:56.583 improved patient satisfaction.

NOTE Confidence: 0.783603353333334

00:13:59.200 --> 00:14:01.915 Um? This highlights some of

NOTE Confidence: 0.783603353333334

00:14:01.915 --> 00:14:04.087 the innovative projects that

NOTE Confidence: 0.783603353333334

00:14:04.087 --> 00:14:06.830 we've taken on in the network.

NOTE Confidence: 0.783603353333334

00:14:06.830 --> 00:14:09.294 This was a pilot with Asko Asko
NOTE Confidence: 0.7836033533333334

00:14:09.294 --> 00:14:11.745 has a quality training program that
NOTE Confidence: 0.7836033533333334

00:14:11.745 --> 00:14:14.811 is 6 months and has three didactic
NOTE Confidence: 0.7836033533333334

00:14:14.894 --> 00:14:17.756 sessions and and a very aggressive
NOTE Confidence: 0.7836033533333334

00:14:17.756 --> 00:14:20.135 curriculum every two weeks around
NOTE Confidence: 0.7836033533333334

00:14:20.135 --> 00:14:22.460 process mapping and barrier analysis
NOTE Confidence: 0.7836033533333334

00:14:22.460 --> 00:14:25.240 and and ultimately multiple PDS a cycles.
NOTE Confidence: 0.7836033533333334

00:14:25.240 --> 00:14:28.592 In this case, we had a team from
NOTE Confidence: 0.7836033533333334

00:14:28.592 --> 00:14:32.156 every care center at the time in 2000.
NOTE Confidence: 0.7836033533333334

00:14:32.160 --> 00:14:35.316 17 and we did it again,
NOTE Confidence: 0.7836033533333334

00:14:35.320 --> 00:14:37.960 2018 which were interdisciplinary team.
NOTE Confidence: 0.7836033533333334

00:14:37.960 --> 00:14:40.590 So we had doctors partnering
NOTE Confidence: 0.7836033533333334

00:14:40.590 --> 00:14:42.694 with nurses or nutrition,
NOTE Confidence: 0.7836033533333334

00:14:42.700 --> 00:14:46.220 or and in one case in MA Pharmacy
NOTE Confidence: 0.7836033533333334

00:14:46.220 --> 00:14:48.440 to conduct quality improvement
NOTE Confidence: 0.7836033533333334

00:14:48.440 --> 00:14:52.780 projects and all of those groups were

NOTE Confidence: 0.783603353333334

00:14:52.780 --> 00:14:56.398 able to complete at least one PDS,

NOTE Confidence: 0.783603353333334

00:14:56.400 --> 00:15:00.616 a cycle over two years or each year,

NOTE Confidence: 0.783603353333334

00:15:00.620 --> 00:15:02.580 each year getting through.

NOTE Confidence: 0.783603353333334

00:15:02.580 --> 00:15:05.520 Ipedia say cycle and this work

NOTE Confidence: 0.783603353333334

00:15:05.614 --> 00:15:08.719 ultimately resulted in nine story

NOTE Confidence: 0.783603353333334

00:15:08.719 --> 00:15:11.203 in five national presentations,

NOTE Confidence: 0.783603353333334

00:15:11.210 --> 00:15:15.026 and one of those projects that

NOTE Confidence: 0.783603353333334

00:15:15.026 --> 00:15:18.891 Jane Kanowitz lead in water Ferd

NOTE Confidence: 0.783603353333334

00:15:18.891 --> 00:15:23.084 in in 2018 is actually the care

NOTE Confidence: 0.783603353333334

00:15:23.084 --> 00:15:26.497 center quality goal for 2021.

NOTE Confidence: 0.783603353333334

00:15:26.500 --> 00:15:27.190 Um?

NOTE Confidence: 0.85358703

00:15:29.440 --> 00:15:32.380 I think many of the participants in

NOTE Confidence: 0.85358703

00:15:32.380 --> 00:15:34.494 these projects were really energized

NOTE Confidence: 0.85358703

00:15:34.494 --> 00:15:37.606 by the teams and the and what they

NOTE Confidence: 0.85358703

00:15:37.687 --> 00:15:40.359 learned around quality improvement.

NOTE Confidence: 0.85358703

00:15:40.360 --> 00:15:42.635 And one question was how
NOTE Confidence: 0.85358703

00:15:42.635 --> 00:15:44.910 do we sustain that gain?
NOTE Confidence: 0.85358703

00:15:44.910 --> 00:15:48.263 You know, I think that it's it's
NOTE Confidence: 0.85358703

00:15:48.263 --> 00:15:51.127 those it's important to be able to
NOTE Confidence: 0.85358703

00:15:51.127 --> 00:15:54.293 use those tools in Q I2 to better
NOTE Confidence: 0.85358703

00:15:54.293 --> 00:15:56.958 care and recognize opportunities to
NOTE Confidence: 0.85358703

00:15:56.958 --> 00:16:00.009 reuse them to face challenges and.
NOTE Confidence: 0.85358703

00:16:00.009 --> 00:16:02.907 And this is actually what we're
NOTE Confidence: 0.85358703

00:16:02.907 --> 00:16:05.547 doing now in the ambulatory
NOTE Confidence: 0.85358703

00:16:05.547 --> 00:16:08.137 transformation Work group we have.
NOTE Confidence: 0.85358703

00:16:08.140 --> 00:16:10.588 A number of groups that are
NOTE Confidence: 0.85358703

00:16:10.588 --> 00:16:13.214 really using the same Qi tools
NOTE Confidence: 0.85358703

00:16:13.214 --> 00:16:15.474 and change tools in lockstep.
NOTE Confidence: 0.85358703

00:16:15.480 --> 00:16:17.470 Action across multiple teams to
NOTE Confidence: 0.85358703

00:16:17.470 --> 00:16:20.016 respond to the pandemic and work
NOTE Confidence: 0.85358703

00:16:20.016 --> 00:16:21.960 towards transformation of care,

NOTE Confidence: 0.85358703

00:16:21.960 --> 00:16:24.040 whether it's relocation of sites

NOTE Confidence: 0.85358703

00:16:24.040 --> 00:16:26.720 or rapid uptake of Tele health.

NOTE Confidence: 0.85358703

00:16:26.720 --> 00:16:28.013 Or you know,

NOTE Confidence: 0.85358703

00:16:28.013 --> 00:16:30.168 developing and disseminating best practices.

NOTE Confidence: 0.85358703

00:16:30.170 --> 00:16:33.586 I think that this this this is the

NOTE Confidence: 0.85358703

00:16:33.586 --> 00:16:36.279 same process as the ASCO Smiler

NOTE Confidence: 0.85358703

00:16:36.279 --> 00:16:38.895 pilot but now applied to the.

NOTE Confidence: 0.85358703

00:16:38.900 --> 00:16:39.630 Immediate.

NOTE Confidence: 0.69316995

00:16:42.500 --> 00:16:44.330 Covid pandemic.

NOTE Confidence: 0.8512973

00:16:46.340 --> 00:16:49.028 Now that we're in, so you,

NOTE Confidence: 0.8512973

00:16:49.030 --> 00:16:52.159 I think you'll hear more about these.

NOTE Confidence: 0.8512973

00:16:52.160 --> 00:16:54.400 The work these groups are

NOTE Confidence: 0.8512973

00:16:54.400 --> 00:16:56.640 doing over the coming months,

NOTE Confidence: 0.8512973

00:16:56.640 --> 00:17:01.148 and I think it's been really exciting.

NOTE Confidence: 0.8512973

00:17:01.150 --> 00:17:04.385 So now I'm going to turn to clinical

NOTE Confidence: 0.8512973

00:17:04.385 --> 00:17:06.810 research, and as I mentioned before,
NOTE Confidence: 0.8512973

00:17:06.810 --> 00:17:10.002 we have about 25% of our YCC therapeutic
NOTE Confidence: 0.8512973

00:17:10.002 --> 00:17:12.058 enrollments from the care centers.
NOTE Confidence: 0.8512973

00:17:12.060 --> 00:17:14.250 This is also a process that
NOTE Confidence: 0.8512973

00:17:14.250 --> 00:17:16.909 needed to be built and hardwired.
NOTE Confidence: 0.8512973

00:17:16.910 --> 00:17:18.930 This is back in 2012.
NOTE Confidence: 0.8512973

00:17:18.930 --> 00:17:22.031 We had three cooperative group trials open
NOTE Confidence: 0.8512973

00:17:22.031 --> 00:17:25.786 and we had to figure out how to do ESO.
NOTE Confidence: 0.8512973

00:17:25.790 --> 00:17:28.394 Peas, around drug shipment and lab
NOTE Confidence: 0.8512973

00:17:28.394 --> 00:17:31.178 processing and training the staff and the.
NOTE Confidence: 0.8512973

00:17:31.180 --> 00:17:33.903 The docs to do trials where they
NOTE Confidence: 0.8512973

00:17:33.903 --> 00:17:36.228 hadn't done that before and as
NOTE Confidence: 0.8512973

00:17:36.228 --> 00:17:38.727 well as the Pisa trials to make
NOTE Confidence: 0.8512973

00:17:38.816 --> 00:17:41.041 sure that they were comfortable
NOTE Confidence: 0.8512973

00:17:41.041 --> 00:17:43.718 and had oversight of the process.
NOTE Confidence: 0.8512973

00:17:43.718 --> 00:17:46.406 Overtime we developed a monthly clinical

NOTE Confidence: 0.8512973

00:17:46.406 --> 00:17:48.931 research working group that has research

NOTE Confidence: 0.8512973

00:17:48.931 --> 00:17:51.169 champions from each site that meet

NOTE Confidence: 0.8512973

00:17:51.169 --> 00:17:53.348 monthly and vote on their portfolio.

NOTE Confidence: 0.8512973

00:17:53.350 --> 00:17:55.305 The disease team leaders come

NOTE Confidence: 0.8512973

00:17:55.305 --> 00:17:57.260 to those meetings and present

NOTE Confidence: 0.8512973

00:17:57.332 --> 00:17:59.387 their portfolio and new trials,

NOTE Confidence: 0.8512973

00:17:59.390 --> 00:18:03.358 and I think that this process is really.

NOTE Confidence: 0.8512973

00:18:03.360 --> 00:18:07.000 Grown obviously here in the next slide you

NOTE Confidence: 0.8512973

00:18:07.000 --> 00:18:10.842 can see that the accrual per the yearly

NOTE Confidence: 0.8512973

00:18:10.842 --> 00:18:14.469 accrual by sight and the highest sites.

NOTE Confidence: 0.8512973

00:18:14.470 --> 00:18:16.398 Saint Francis Northaven Trumbull,

NOTE Confidence: 0.8512973

00:18:16.398 --> 00:18:16.880 Fairfield.

NOTE Confidence: 0.8512973

00:18:16.880 --> 00:18:21.000 I think one of the things we've learned

NOTE Confidence: 0.8512973

00:18:21.000 --> 00:18:25.368 is that they need to have or they have

NOTE Confidence: 0.8512973

00:18:25.368 --> 00:18:29.827 a ACRSL lab which allows all protocols.

NOTE Confidence: 0.8512973

00:18:29.830 --> 00:18:31.411 No, let's which.
NOTE Confidence: 0.8512973

00:18:31.411 --> 00:18:35.682 Means that there's no limit on protocols that
NOTE Confidence: 0.8512973

00:18:35.682 --> 00:18:39.546 they can open due to lab processing times.
NOTE Confidence: 0.8512973

00:18:39.550 --> 00:18:41.350 Certainly the 2020 accrual
NOTE Confidence: 0.8512973

00:18:41.350 --> 00:18:43.600 was affected by Covid Inc.
NOTE Confidence: 0.8512973

00:18:43.600 --> 00:18:47.632 In our in 2018 we had 224 this year.
NOTE Confidence: 0.8512973

00:18:47.640 --> 00:18:50.496 If you take out the months that
NOTE Confidence: 0.8512973

00:18:50.496 --> 00:18:54.000 we had covid and we had very good
NOTE Confidence: 0.8512973

00:18:54.000 --> 00:18:56.762 accrual prior and and have really
NOTE Confidence: 0.8512973

00:18:56.762 --> 00:19:00.143 picked up now we would have certainly
NOTE Confidence: 0.8512973

00:19:00.143 --> 00:19:04.298 hit 200 between 200 and 220.
NOTE Confidence: 0.8512973

00:19:04.300 --> 00:19:06.808 If not for the for covid,
NOTE Confidence: 0.8512973

00:19:06.810 --> 00:19:09.318 so we activated a new site
NOTE Confidence: 0.8512973

00:19:09.318 --> 00:19:10.990 this year in Westerly.
NOTE Confidence: 0.8512973

00:19:10.990 --> 00:19:15.070 They are now treating some of the patients
NOTE Confidence: 0.8512973

00:19:15.070 --> 00:19:18.690 who were started in Waterford and.

NOTE Confidence: 0.8512973

00:19:18.690 --> 00:19:19.037 Now,

NOTE Confidence: 0.8512973

00:19:19.037 --> 00:19:21.119 in Rhode Island and you can

NOTE Confidence: 0.8512973

00:19:21.119 --> 00:19:23.179 see it actually in Waterford,

NOTE Confidence: 0.8512973

00:19:23.180 --> 00:19:25.050 which opened three years ago.

NOTE Confidence: 0.8512973

00:19:25.050 --> 00:19:26.542 There's been really great

NOTE Confidence: 0.8512973

00:19:26.542 --> 00:19:28.407 accrual growth there as well,

NOTE Confidence: 0.8512973

00:19:28.410 --> 00:19:30.744 so I think that there's really

NOTE Confidence: 0.8512973

00:19:30.744 --> 00:19:33.331 a lot of potential here if the

NOTE Confidence: 0.8512973

00:19:33.331 --> 00:19:35.518 next slide shows you the the

NOTE Confidence: 0.8512973

00:19:35.518 --> 00:19:37.388 yearly accrual by the DART.

NOTE Confidence: 0.8512973

00:19:37.390 --> 00:19:39.903 So which kinds of trials are are

NOTE Confidence: 0.8512973

00:19:39.903 --> 00:19:42.198 having the best accrual breast in

NOTE Confidence: 0.8512973

00:19:42.198 --> 00:19:44.865 GI have are certainly at the top.

NOTE Confidence: 0.82509637

00:19:46.940 --> 00:19:50.180 The long and heme are not far behind as

NOTE Confidence: 0.82509637

00:19:50.180 --> 00:19:53.329 well as T rad ngu that are increasing,

NOTE Confidence: 0.82509637

00:19:53.330 --> 00:19:55.920 so I think again, there's a tremendous

NOTE Confidence: 0.82509637

00:19:55.920 --> 00:19:58.219 potential here in the care centers,

NOTE Confidence: 0.82509637

00:19:58.220 --> 00:20:00.260 and as we have all.

NOTE Confidence: 0.82509637

00:20:00.260 --> 00:20:02.366 Our docs aligning with disease teams.

NOTE Confidence: 0.82509637

00:20:02.370 --> 00:20:05.586 I think this will just increase

NOTE Confidence: 0.82509637

00:20:05.586 --> 00:20:10.220 in the future. Um, this is the.

NOTE Confidence: 0.82509637

00:20:10.220 --> 00:20:12.240 I will quote Kurt Sabbath,

NOTE Confidence: 0.82509637

00:20:12.240 --> 00:20:15.372 who is one of our care center docs who

NOTE Confidence: 0.82509637

00:20:15.372 --> 00:20:17.899 helped to lead research initially.

NOTE Confidence: 0.82509637

00:20:17.900 --> 00:20:21.700 Now now hand it over to Neil Fishback.

NOTE Confidence: 0.82509637

00:20:21.700 --> 00:20:24.372 Kurt always said that he felt that clinical

NOTE Confidence: 0.82509637

00:20:24.372 --> 00:20:26.560 research is synonymous with quality,

NOTE Confidence: 0.82509637

00:20:26.560 --> 00:20:28.056 quality care because there's

NOTE Confidence: 0.82509637

00:20:28.056 --> 00:20:30.300 so many eyes on the patient.

NOTE Confidence: 0.82509637

00:20:30.300 --> 00:20:31.796 There's so much emphasis

NOTE Confidence: 0.82509637

00:20:31.796 --> 00:20:32.918 on important communication,

NOTE Confidence: 0.82509637
00:20:32.920 --> 00:20:34.039 shared decision making,
NOTE Confidence: 0.82509637
00:20:34.039 --> 00:20:35.904 and that really epitomizes quality.
NOTE Confidence: 0.82509637
00:20:35.910 --> 00:20:36.888 In our case,
NOTE Confidence: 0.82509637
00:20:36.888 --> 00:20:38.844 the vision had always been to
NOTE Confidence: 0.82509637
00:20:38.844 --> 00:20:40.903 to provide research as access
NOTE Confidence: 0.82509637
00:20:40.903 --> 00:20:43.381 to our patients close at home,
NOTE Confidence: 0.82509637
00:20:43.390 --> 00:20:45.580 and I think that even more
NOTE Confidence: 0.82509637
00:20:45.580 --> 00:20:47.510 than the numbers per site,
NOTE Confidence: 0.82509637
00:20:47.510 --> 00:20:49.748 this is what really strikes me.
NOTE Confidence: 0.82509637
00:20:49.750 --> 00:20:52.090 Every year we have somewhere around.
NOTE Confidence: 0.82509637
00:20:52.090 --> 00:20:55.074 85 to 87% of our physicians who put
NOTE Confidence: 0.82509637
00:20:55.074 --> 00:20:57.860 at least one patient onto trial.
NOTE Confidence: 0.82509637
00:20:57.860 --> 00:21:01.148 So I think we really changed that culture.
NOTE Confidence: 0.82509637
00:21:01.150 --> 00:21:04.034 We've had a research summit every year,
NOTE Confidence: 0.82509637
00:21:04.040 --> 00:21:05.812 usually around 80 people.
NOTE Confidence: 0.82509637

00:21:05.812 --> 00:21:09.284 That includes our care center docs or DART

NOTE Confidence: 0.82509637

00:21:09.284 --> 00:21:11.867 team members or CTO staff get prizes.

NOTE Confidence: 0.82509637

00:21:11.870 --> 00:21:14.468 We have about 13 care center

NOTE Confidence: 0.82509637

00:21:14.468 --> 00:21:17.018 physicians who served as PII on

NOTE Confidence: 0.82509637

00:21:17.018 --> 00:21:19.587 trials and right now we have 83

NOTE Confidence: 0.82509637

00:21:19.587 --> 00:21:22.248 trials open in nine disease types.

NOTE Confidence: 0.82509637

00:21:22.250 --> 00:21:25.710 About 50% cooperative group 43%

NOTE Confidence: 0.82509637

00:21:25.710 --> 00:21:31.020 industry sponsored in 10% IIT's.

NOTE Confidence: 0.82509637

00:21:31.020 --> 00:21:33.840 Here you see that our care

NOTE Confidence: 0.82509637

00:21:33.840 --> 00:21:36.080 center accruals form about 60%

NOTE Confidence: 0.82509637

00:21:36.080 --> 00:21:38.380 of our cooperative group trials,

NOTE Confidence: 0.82509637

00:21:38.380 --> 00:21:41.728 so that's really important.

NOTE Confidence: 0.82509637

00:21:41.730 --> 00:21:44.118 This is one of my trials.

NOTE Confidence: 0.82509637

00:21:44.120 --> 00:21:46.766 This is a national trial that we

NOTE Confidence: 0.82509637

00:21:46.766 --> 00:21:49.213 have opened in about guess 900

NOTE Confidence: 0.82509637

00:21:49.213 --> 00:21:51.679 sites across the US in Canada,

NOTE Confidence: 0.82509637

00:21:51.680 --> 00:21:54.466 but in our care centers as well.

NOTE Confidence: 0.82509637

00:21:54.470 --> 00:21:56.762 I'm National Co chair with has

NOTE Confidence: 0.82509637

00:21:56.762 --> 00:22:00.026 poor guy and it's a first line PDL

NOTE Confidence: 0.82509637

00:22:00.026 --> 00:22:02.510 positive trial for non squamous non

NOTE Confidence: 0.82509637

00:22:02.589 --> 00:22:05.645 small cell and I think that this is

NOTE Confidence: 0.82509637

00:22:05.645 --> 00:22:07.990 an important trial because it either

NOTE Confidence: 0.82509637

00:22:07.990 --> 00:22:10.360 randomizes you 2 two arms which

NOTE Confidence: 0.82509637

00:22:10.438 --> 00:22:12.558 start with immunotherapy and then

NOTE Confidence: 0.82509637

00:22:12.558 --> 00:22:15.399 if you progress you going to chemo.

NOTE Confidence: 0.82509637

00:22:15.400 --> 00:22:18.165 Or you add chemo to the pen

NOTE Confidence: 0.82509637

00:22:18.165 --> 00:22:19.350 bro Appan progression.

NOTE Confidence: 0.82509637

00:22:19.350 --> 00:22:21.026 That's an important question.

NOTE Confidence: 0.82509637

00:22:21.026 --> 00:22:24.733 This is the the chemo IO control arm and

NOTE Confidence: 0.82509637

00:22:24.733 --> 00:22:28.039 and this this trial I think will tell us.

NOTE Confidence: 0.82509637

00:22:28.040 --> 00:22:28.830 Very important.

NOTE Confidence: 0.8432984

00:22:30.900 --> 00:22:33.567 Give us information on sequencing of chemo.

NOTE Confidence: 0.8432984

00:22:33.570 --> 00:22:35.850 If you can spare it upfront.

NOTE Confidence: 0.8432984

00:22:35.850 --> 00:22:38.076 If you add it to the

NOTE Confidence: 0.8432984

00:22:38.076 --> 00:22:40.040 immunotherapy if that will help.

NOTE Confidence: 0.8432984

00:22:40.040 --> 00:22:41.945 And ultimately because we are

NOTE Confidence: 0.8432984

00:22:41.945 --> 00:22:43.850 collecting tissue from this trial,

NOTE Confidence: 0.8432984

00:22:43.850 --> 00:22:46.436 we're going to be looking for

NOTE Confidence: 0.8432984

00:22:46.436 --> 00:22:48.650 prognostic signatures for Pember Lizum

NOTE Confidence: 0.8432984

00:22:48.650 --> 00:22:50.735 app and predictive signatures for

NOTE Confidence: 0.8432984

00:22:50.735 --> 00:22:53.450 addition of chemo to immunotherapy.

NOTE Confidence: 0.8432984

00:22:53.450 --> 00:22:56.609 This is also an IIT of mine in small

NOTE Confidence: 0.8432984

00:22:56.609 --> 00:22:59.365 cell which with the biopsy upfront

NOTE Confidence: 0.8432984

00:22:59.365 --> 00:23:02.769 and then on treatment at week four

NOTE Confidence: 0.8432984

00:23:02.769 --> 00:23:05.279 after after treatment with EPI,

NOTE Confidence: 0.8432984

00:23:05.280 --> 00:23:08.346 Nevo and this trial has 17 patients

NOTE Confidence: 0.8432984

00:23:08.346 --> 00:23:11.978 who started on it with 10 paired pre

NOTE Confidence: 0.8432984

00:23:11.978 --> 00:23:14.714 and on treatment biopsies and this

NOTE Confidence: 0.8432984

00:23:14.714 --> 00:23:18.002 trial is open in our network and we've

NOTE Confidence: 0.8432984

00:23:18.002 --> 00:23:21.048 had 11 accruals from our network and

NOTE Confidence: 0.8432984

00:23:21.048 --> 00:23:23.500 I think that's important because.

NOTE Confidence: 0.8432984

00:23:23.500 --> 00:23:26.135 Talking to colleagues of bars

NOTE Confidence: 0.8432984

00:23:26.135 --> 00:23:29.314 across the country who have networks

NOTE Confidence: 0.8432984

00:23:29.314 --> 00:23:32.008 and who are trying to do.

NOTE Confidence: 0.8432984

00:23:32.010 --> 00:23:33.995 Clinical trials they've really relied

NOTE Confidence: 0.8432984

00:23:33.995 --> 00:23:35.980 on industry sponsored the cooperative,

NOTE Confidence: 0.8432984

00:23:35.980 --> 00:23:38.668 and very few actually have have

NOTE Confidence: 0.8432984

00:23:38.668 --> 00:23:41.630 diploid lits in in the network.

NOTE Confidence: 0.8432984

00:23:41.630 --> 00:23:45.078 So this this just shows you a number

NOTE Confidence: 0.8432984

00:23:45.078 --> 00:23:49.273 of the items that we have and you can

NOTE Confidence: 0.8432984

00:23:49.273 --> 00:23:53.026 see that here's 12 accruals or 30% of

NOTE Confidence: 0.8432984

00:23:53.026 --> 00:23:54.850 Doctor Lacey's modified folfirinox,

NOTE Confidence: 0.8432984

00:23:54.850 --> 00:23:58.049 and in this case Doctor Kim Johans.
NOTE Confidence: 0.8432984

00:23:58.050 --> 00:24:01.778 That's 88% of her seven out of eight
NOTE Confidence: 0.8432984

00:24:01.778 --> 00:24:04.427 accruals for her and you know,
NOTE Confidence: 0.8432984

00:24:04.430 --> 00:24:05.798 for Doctor Nipper,
NOTE Confidence: 0.8432984

00:24:05.798 --> 00:24:09.054 it's a 4040% of her her accruals
NOTE Confidence: 0.8432984

00:24:09.054 --> 00:24:11.880 for her IIT as well so.
NOTE Confidence: 0.8432984

00:24:11.880 --> 00:24:16.003 I think this is really important research
NOTE Confidence: 0.8432984

00:24:16.003 --> 00:24:20.618 and support of our investigators at Yale.
NOTE Confidence: 0.8432984

00:24:20.620 --> 00:24:23.038 So what is the future hold?
NOTE Confidence: 0.8432984

00:24:23.040 --> 00:24:24.315 Among other things,
NOTE Confidence: 0.8432984

00:24:24.315 --> 00:24:26.865 I think there are certainly opportunities
NOTE Confidence: 0.8432984

00:24:26.865 --> 00:24:28.759 for building multidisciplinary care
NOTE Confidence: 0.8432984

00:24:28.759 --> 00:24:31.549 to enhance our Smiler signature of
NOTE Confidence: 0.8432984

00:24:31.549 --> 00:24:33.923 care in the network and to build
NOTE Confidence: 0.8432984

00:24:33.923 --> 00:24:35.151 on our current Med.
NOTE Confidence: 0.8432984

00:24:35.160 --> 00:24:36.955 Onken Hemang Craddock networks to

NOTE Confidence: 0.8432984

00:24:36.955 --> 00:24:38.750 support and our surgical oncology

NOTE Confidence: 0.8432984

00:24:38.806 --> 00:24:39.610 representation.

NOTE Confidence: 0.8432984

00:24:39.610 --> 00:24:41.700 We are developing formalized multi

NOTE Confidence: 0.8432984

00:24:41.700 --> 00:24:44.751 D clinics and that some of the work

NOTE Confidence: 0.8432984

00:24:44.751 --> 00:24:47.385 that I'm going to carry on in my

NOTE Confidence: 0.8432984

00:24:47.385 --> 00:24:49.345 integration role and strengthen

NOTE Confidence: 0.8432984

00:24:49.345 --> 00:24:51.795 our alignment with disease teams.

NOTE Confidence: 0.8432984

00:24:51.800 --> 00:24:53.905 And certainly our disease centers

NOTE Confidence: 0.8432984

00:24:53.905 --> 00:24:55.589 to provide service excellence

NOTE Confidence: 0.8432984

00:24:55.589 --> 00:24:57.710 and positive patient outcomes.

NOTE Confidence: 0.8432984

00:24:57.710 --> 00:24:59.690 This is my favorite slide.

NOTE Confidence: 0.8432984

00:24:59.690 --> 00:25:02.850 This is what I think is the most

NOTE Confidence: 0.8432984

00:25:02.850 --> 00:25:05.268 exciting piece of all of this

NOTE Confidence: 0.8432984

00:25:05.268 --> 00:25:07.584 is not not numbers of patients,

NOTE Confidence: 0.8432984

00:25:07.590 --> 00:25:10.854 but really I think the faculty that have

NOTE Confidence: 0.8432984

00:25:10.854 --> 00:25:13.910 joined his care center is one of them.
NOTE Confidence: 0.8432984

00:25:13.910 --> 00:25:16.328 Francesca is going to give a
NOTE Confidence: 0.8432984

00:25:16.328 --> 00:25:18.250 grand rounds right after me.
NOTE Confidence: 0.8432984

00:25:18.250 --> 00:25:20.218 They all master clinicians.
NOTE Confidence: 0.8432984

00:25:20.218 --> 00:25:23.170 They have devoted their really the
NOTE Confidence: 0.8432984

00:25:23.254 --> 00:25:26.173 clinical arm of a female cancer and
NOTE Confidence: 0.8432984

00:25:26.173 --> 00:25:28.426 smilow cancer hospital within the
NOTE Confidence: 0.8432984

00:25:28.426 --> 00:25:31.180 within the community and all have
NOTE Confidence: 0.8432984

00:25:31.261 --> 00:25:33.463 joined with the disease teams to
NOTE Confidence: 0.8432984

00:25:33.463 --> 00:25:36.528 do you know any number of really
NOTE Confidence: 0.8432984

00:25:36.528 --> 00:25:37.538 exciting things.
NOTE Confidence: 0.8432984

00:25:37.540 --> 00:25:39.730 BPI on trials do collaborative
NOTE Confidence: 0.8432984

00:25:39.730 --> 00:25:42.110 research projects, develop Qi projects,
NOTE Confidence: 0.8432984

00:25:42.110 --> 00:25:45.110 help teaching our house staff and
NOTE Confidence: 0.8432984

00:25:45.110 --> 00:25:48.065 anymore so it has really been my
NOTE Confidence: 0.8432984

00:25:48.065 --> 00:25:50.482 honor to represent these folks and

NOTE Confidence: 0.8432984

00:25:50.482 --> 00:25:54.970 to work with them. And I I can't.

NOTE Confidence: 0.8432984

00:25:54.970 --> 00:25:57.502 I can't emphasize enough that it's

NOTE Confidence: 0.8432984

00:25:57.502 --> 00:25:59.807 really been a work collaborative

NOTE Confidence: 0.8432984

00:25:59.807 --> 00:26:01.881 work of many, many,

NOTE Confidence: 0.8432984

00:26:01.881 --> 00:26:05.108 many hands to to build the network,

NOTE Confidence: 0.8432984

00:26:05.110 --> 00:26:06.954 including Charlie and Lori.

NOTE Confidence: 0.8432984

00:26:06.954 --> 00:26:07.876 Kevin Billingsley,

NOTE Confidence: 0.8432984

00:26:07.880 --> 00:26:10.640 Kim's lesser art flim, Aleesa Chomsky,

NOTE Confidence: 0.8432984

00:26:10.640 --> 00:26:12.484 Monica Fradkin, Connie Engelking,

NOTE Confidence: 0.8432984

00:26:12.484 --> 00:26:13.406 Roy Herbst,

NOTE Confidence: 0.7473088

00:26:13.410 --> 00:26:16.176 Stephanie Pauline, have invested so forth.

NOTE Confidence: 0.7473088

00:26:16.180 --> 00:26:19.748 Jeremy Court Manske will take over as the

NOTE Confidence: 0.7473088

00:26:19.748 --> 00:26:22.605 Chief Network Officer for Medical Services

NOTE Confidence: 0.7473088

00:26:22.605 --> 00:26:25.920 and head up the medication he Monk.

NOTE Confidence: 0.7473088

00:26:25.920 --> 00:26:28.712 And I will be focused on really developing

NOTE Confidence: 0.7473088

00:26:28.712 --> 00:26:30.793 the service lines and integration
NOTE Confidence: 0.7473088

00:26:30.793 --> 00:26:32.978 with our delivery care networks.
NOTE Confidence: 0.7473088

00:26:32.980 --> 00:26:36.956 So thank you for the time and.
NOTE Confidence: 0.7473088

00:26:36.960 --> 00:26:39.744 Think I. I'm done so I'd love to
NOTE Confidence: 0.7473088

00:26:39.744 --> 00:26:42.227 answer any questions if if there
NOTE Confidence: 0.8440994

00:26:42.230 --> 00:26:44.344 were any. Thanks and that was wonderful.
NOTE Confidence: 0.8440994

00:26:44.350 --> 00:26:46.240 And congratulations on a very well
NOTE Confidence: 0.8440994

00:26:46.240 --> 00:26:47.979 deserved promotion and we see why.
NOTE Confidence: 0.8440994

00:26:47.980 --> 00:26:49.798 So we have a few questions.
NOTE Confidence: 0.8440994

00:26:49.800 --> 00:26:51.618 Please put them in the chat.
NOTE Confidence: 0.8440994

00:26:51.620 --> 00:26:53.790 Melinda Erling comments were lucky to have
NOTE Confidence: 0.8440994

00:26:53.790 --> 00:26:55.558 this infrastructure with the care centers.
NOTE Confidence: 0.8440994

00:26:55.560 --> 00:26:57.716 I know a lot of non therapeutic
NOTE Confidence: 0.8440994

00:26:57.716 --> 00:26:59.566 interventional research being done in the
NOTE Confidence: 0.8440994

00:26:59.566 --> 00:27:01.312 care centers related to tobacco control,
NOTE Confidence: 0.8440994

00:27:01.320 --> 00:27:03.112 nutrition, exercise and obesity,

NOTE Confidence: 0.8440994

00:27:03.112 --> 00:27:06.748 so I will just follow up and say no.

NOTE Confidence: 0.8440994

00:27:06.750 --> 00:27:07.533 Make it secure.

NOTE Confidence: 0.8440994

00:27:07.533 --> 00:27:09.099 Diverse state as you go up

NOTE Confidence: 0.8440994

00:27:09.099 --> 00:27:10.610 and down the 95 corridor.

NOTE Confidence: 0.8440994

00:27:10.610 --> 00:27:12.546 How are we trying to help increase the

NOTE Confidence: 0.8440994

00:27:12.546 --> 00:27:14.107 diversity of our patient population at

NOTE Confidence: 0.8440994

00:27:14.107 --> 00:27:16.046 our care centers to get more patients

NOTE Confidence: 0.8440994

00:27:16.046 --> 00:27:17.786 from diverse backgrounds on trials?

NOTE Confidence: 0.8440994

00:27:17.790 --> 00:27:18.822 That's certainly something that

NOTE Confidence: 0.8440994

00:27:18.822 --> 00:27:21.014 we can now do that we have so

NOTE Confidence: 0.8440994

00:27:21.014 --> 00:27:22.479 much integration within the state.

NOTE Confidence: 0.905967

00:27:24.830 --> 00:27:26.226 Great great great question.

NOTE Confidence: 0.905967

00:27:26.226 --> 00:27:28.997 I'm just going to go back and share

NOTE Confidence: 0.905967

00:27:28.997 --> 00:27:31.118 my screen again so you can see

NOTE Confidence: 0.905967

00:27:31.118 --> 00:27:33.135 who's doing a lot of this work.

NOTE Confidence: 0.905967

00:27:33.140 --> 00:27:36.388 You know, Melinda, that's a that's a

NOTE Confidence: 0.905967

00:27:36.388 --> 00:27:38.915 planted question because we just put

NOTE Confidence: 0.905967

00:27:38.915 --> 00:27:41.365 together a narrow one to study the

NOTE Confidence: 0.905967

00:27:41.448 --> 00:27:44.418 lean interventions in the care centers,

NOTE Confidence: 0.905967

00:27:44.420 --> 00:27:48.044 and I think that's going to be really

NOTE Confidence: 0.905967

00:27:48.044 --> 00:27:50.500 exciting groups if you look here.

NOTE Confidence: 0.905967

00:27:50.500 --> 00:27:52.738 This is Andrea Silver and she's

NOTE Confidence: 0.905967

00:27:52.738 --> 00:27:56.139 done a lot of work actually devoted,

NOTE Confidence: 0.905967

00:27:56.140 --> 00:27:59.241 you know, one of her passions is

NOTE Confidence: 0.905967

00:27:59.241 --> 00:28:01.903 in in increasing under increasing

NOTE Confidence: 0.905967

00:28:01.903 --> 00:28:04.375 representation of of of.

NOTE Confidence: 0.905967

00:28:04.380 --> 00:28:06.460 In clinical trials and and

NOTE Confidence: 0.905967

00:28:06.460 --> 00:28:08.124 addressing disparities of care,

NOTE Confidence: 0.905967

00:28:08.130 --> 00:28:11.049 and she's done a number of things,

NOTE Confidence: 0.905967

00:28:11.050 --> 00:28:12.718 including that grant the

NOTE Confidence: 0.905967

00:28:12.718 --> 00:28:14.803 initial grant called own it,

NOTE Confidence: 0.905967

00:28:14.810 --> 00:28:17.450 which was oncology works

NOTE Confidence: 0.905967

00:28:17.450 --> 00:28:20.090 with New Haven getting.

NOTE Confidence: 0.905967

00:28:20.090 --> 00:28:21.287 Community representatives to

NOTE Confidence: 0.905967

00:28:21.287 --> 00:28:24.080 weigh in on what kind of research

NOTE Confidence: 0.905967

00:28:24.144 --> 00:28:26.512 is done in the in at smilow and

NOTE Confidence: 0.905967

00:28:26.512 --> 00:28:28.070 building those relationships.

NOTE Confidence: 0.905967

00:28:28.070 --> 00:28:30.830 I think that you know our our latest

NOTE Confidence: 0.905967

00:28:30.830 --> 00:28:33.009 cancer Grant has been incredibly.

NOTE Confidence: 0.86750257

00:28:35.340 --> 00:28:37.556 You know there's been a big focus on

NOTE Confidence: 0.86750257

00:28:37.556 --> 00:28:39.404 trying to increase representation of of

NOTE Confidence: 0.86750257

00:28:39.404 --> 00:28:42.519 of of folks in our in our clinical trials,

NOTE Confidence: 0.86750257

00:28:42.520 --> 00:28:45.008 and that certainly is a focus for us.

NOTE Confidence: 0.812013

00:28:46.500 --> 00:28:48.040 Right, that's that wonderful one.

NOTE Confidence: 0.812013

00:28:48.040 --> 00:28:48.650 More question.

NOTE Confidence: 0.812013

00:28:48.650 --> 00:28:50.175 And then we'll move on.

NOTE Confidence: 0.812013

00:28:50.180 --> 00:28:51.408 Someone comments. It's amazing
NOTE Confidence: 0.812013

00:28:51.408 --> 00:28:53.250 how you built these tumor boards,
NOTE Confidence: 0.812013

00:28:53.250 --> 00:28:55.399 even before anyone knew what zoom was.
NOTE Confidence: 0.812013

00:28:55.400 --> 00:28:57.549 So now that we have zoom in,
NOTE Confidence: 0.812013

00:28:57.550 --> 00:28:59.085 everyone can zoom from their
NOTE Confidence: 0.812013

00:28:59.085 --> 00:29:00.313 phone from their walk.
NOTE Confidence: 0.812013

00:29:00.320 --> 00:29:02.156 Can we use this technology to
NOTE Confidence: 0.812013

00:29:02.156 --> 00:29:02.768 further integrate?
NOTE Confidence: 0.812013

00:29:02.770 --> 00:29:04.146 You know multi modality,
NOTE Confidence: 0.812013

00:29:04.146 --> 00:29:05.866 care subspecialty care with you
NOTE Confidence: 0.812013

00:29:05.866 --> 00:29:08.298 showed us 55 or so doctors around the state.
NOTE Confidence: 0.812013

00:29:08.300 --> 00:29:09.974 Are we using these tools of
NOTE Confidence: 0.812013

00:29:09.974 --> 00:29:11.833 Tele Health to do even better
NOTE Confidence: 0.812013

00:29:11.833 --> 00:29:13.518 now to integrate our care?
NOTE Confidence: 0.81522673

00:29:14.740 --> 00:29:17.631 Yeah, I mean, I think that with
NOTE Confidence: 0.81522673

00:29:17.631 --> 00:29:19.993 covid we've really we toggled up

NOTE Confidence: 0.81522673

00:29:19.993 --> 00:29:22.602 to over 50% of usage and adoption

NOTE Confidence: 0.81522673

00:29:22.602 --> 00:29:24.567 of telehealth during last spring.

NOTE Confidence: 0.81522673

00:29:24.570 --> 00:29:28.007 And and I think that we have.

NOTE Confidence: 0.81522673

00:29:28.010 --> 00:29:30.440 You know initiatives on next day

NOTE Confidence: 0.81522673

00:29:30.440 --> 00:29:32.476 access and improving access that

NOTE Confidence: 0.81522673

00:29:32.476 --> 00:29:34.558 we can utilize Tele health for,

NOTE Confidence: 0.81522673

00:29:34.560 --> 00:29:37.388 and certainly within our multi D clinics

NOTE Confidence: 0.81522673

00:29:37.388 --> 00:29:39.950 were thinking about doing that as well.

NOTE Confidence: 0.81522673

00:29:39.950 --> 00:29:42.830 I think there's a lot of innovation and

NOTE Confidence: 0.81522673

00:29:42.830 --> 00:29:46.109 you know I'll I'll mention you know again,

NOTE Confidence: 0.81522673

00:29:46.110 --> 00:29:46.878 Melinda's talked.

NOTE Confidence: 0.81522673

00:29:46.878 --> 00:29:49.566 I didn't talk about the non therapeutics,

NOTE Confidence: 0.81522673

00:29:49.570 --> 00:29:51.950 but we certainly have used the care

NOTE Confidence: 0.81522673

00:29:51.950 --> 00:29:53.933 centers as places to participate

NOTE Confidence: 0.81522673

00:29:53.933 --> 00:29:55.729 with the smoking cessation.

NOTE Confidence: 0.81522673

00:29:55.730 --> 00:29:58.240 Joe Biden Moon shot initiative.
NOTE Confidence: 0.81522673

00:29:58.240 --> 00:29:59.623 As well as.
NOTE Confidence: 0.81522673

00:29:59.623 --> 00:30:02.389 You know collect samples for Stephanie,
NOTE Confidence: 0.81522673

00:30:02.390 --> 00:30:03.058 Aliens, NDS,
NOTE Confidence: 0.81522673

00:30:03.058 --> 00:30:05.730 registry and and and and you know attempts
NOTE Confidence: 0.81522673

00:30:05.792 --> 00:30:08.096 to understand the science behind that.
NOTE Confidence: 0.81522673

00:30:08.100 --> 00:30:10.740 So I think there's just you know no
NOTE Confidence: 0.81522673

00:30:10.740 --> 00:30:14.064 end to what you can do with with the
NOTE Confidence: 0.81522673

00:30:14.064 --> 00:30:16.667 resources and the team that we have.
NOTE Confidence: 0.83359927

00:30:17.290 --> 00:30:18.730 Great well thanks Anne.
NOTE Confidence: 0.83359927

00:30:18.730 --> 00:30:19.810 Wonderful talking again,
NOTE Confidence: 0.83359927

00:30:19.810 --> 00:30:20.308 congratulations.
NOTE Confidence: 0.83359927

00:30:20.308 --> 00:30:23.296 So we have a second speaker,
NOTE Confidence: 0.83359927

00:30:23.300 --> 00:30:24.820 it's Doctor Francisca Montinari,
NOTE Confidence: 0.83359927

00:30:24.820 --> 00:30:25.580 Doctor Martner.
NOTE Confidence: 0.83359927

00:30:25.580 --> 00:30:27.740 Doctor Martin Ari is an assistant

NOTE Confidence: 0.83359927

00:30:27.740 --> 00:30:29.971 professor of clinical medicine in the

NOTE Confidence: 0.83359927

00:30:29.971 --> 00:30:32.167 hematology section and cares for patients

NOTE Confidence: 0.83359927

00:30:32.167 --> 00:30:34.179 with hematologic malignancies at our

NOTE Confidence: 0.83359927

00:30:34.179 --> 00:30:36.219 southernmost care center in Greenwich.

NOTE Confidence: 0.83359927

00:30:36.220 --> 00:30:38.120 Documentary recently joined Yell from

NOTE Confidence: 0.83359927

00:30:38.120 --> 00:30:40.020 the New York Presbyterian Hospital,

NOTE Confidence: 0.83359927

00:30:40.020 --> 00:30:41.540 Columbia University Medical Center,

NOTE Confidence: 0.83359927

00:30:41.540 --> 00:30:43.440 College of Physicians and Surgeons,

NOTE Confidence: 0.83359927

00:30:43.440 --> 00:30:45.485 which she was assistant Professor

NOTE Confidence: 0.83359927

00:30:45.485 --> 00:30:47.121 of medicine and Experimental

NOTE Confidence: 0.83359927

00:30:47.121 --> 00:30:48.884 Therapies Therapeutics in the

NOTE Confidence: 0.83359927

00:30:48.884 --> 00:30:50.604 Center for Lymphoid Malignancies.

NOTE Confidence: 0.83359927

00:30:50.610 --> 00:30:52.542 Doctor Montanari received her medical degree

NOTE Confidence: 0.83359927

00:30:52.542 --> 00:30:54.610 from the University of Pavia in Italy,

NOTE Confidence: 0.83359927

00:30:54.610 --> 00:30:56.150 which she graduated Magna ***

NOTE Confidence: 0.83359927

00:30:56.150 --> 00:30:57.590 laude and completed both residency
NOTE Confidence: 0.83359927

00:30:57.590 --> 00:30:59.030 and Fellowship and New York
NOTE Confidence: 0.83359927

00:30:59.076 --> 00:31:00.468 University School of Medicine,
NOTE Confidence: 0.83359927

00:31:00.470 --> 00:31:02.252 but she was awarded the Fellow
NOTE Confidence: 0.83359927

00:31:02.252 --> 00:31:03.850 of the Year Teaching Award.
NOTE Confidence: 0.83359927

00:31:03.850 --> 00:31:05.506 She served on the Institutional Review
NOTE Confidence: 0.83359927

00:31:05.506 --> 00:31:07.328 Board Committee and as director of
NOTE Confidence: 0.83359927

00:31:07.328 --> 00:31:08.668 the Institutional Lymphoma Tumor
NOTE Confidence: 0.83359927

00:31:08.668 --> 00:31:10.008 Board at Columbia University,
NOTE Confidence: 0.83359927

00:31:10.010 --> 00:31:11.962 and he is part of the steering committee
NOTE Confidence: 0.83359927

00:31:11.962 --> 00:31:14.019 of the Lymphoma Research Foundation,
NOTE Confidence: 0.83359927

00:31:14.020 --> 00:31:14.566 New York.
NOTE Confidence: 0.83359927

00:31:14.566 --> 00:31:16.477 Lymphoma rounds were so lucky to have
NOTE Confidence: 0.83359927

00:31:16.477 --> 00:31:18.638 been able to recruit Francisca recently,
NOTE Confidence: 0.83359927

00:31:18.640 --> 00:31:21.240 and she's going to talk to us now.
NOTE Confidence: 0.83359927

00:31:21.240 --> 00:31:23.364 About post transplant

NOTE Confidence: 0.83359927

00:31:23.364 --> 00:31:25.488 lymphoproliferative disorders franceska.

NOTE Confidence: 0.89172757

00:31:27.850 --> 00:31:30.310 Thank you for the introduction,

NOTE Confidence: 0.89172757

00:31:30.310 --> 00:31:32.770 so I'll share my screen.

NOTE Confidence: 0.7702043

00:31:37.680 --> 00:31:40.707 OK, so good afternoon everybody.

NOTE Confidence: 0.7702043

00:31:40.707 --> 00:31:44.421 I will review today was transparently

NOTE Confidence: 0.7702043

00:31:44.421 --> 00:31:45.930 proliferative disorders.

NOTE Confidence: 0.7702043

00:31:45.930 --> 00:31:49.759 So here's my disclosures. So we are.

NOTE Confidence: 0.7702043

00:31:49.760 --> 00:31:53.491 We will review together and how PLD

NOTE Confidence: 0.7702043

00:31:53.491 --> 00:31:56.308 are classified according to the

NOTE Confidence: 0.7702043

00:31:56.308 --> 00:31:58.560 most recent WHL classification,

NOTE Confidence: 0.7702043

00:31:58.560 --> 00:32:01.310 the Epidemiology, the risk factors

NOTE Confidence: 0.7702043

00:32:01.310 --> 00:32:04.060 at timing of onset prognosis,

NOTE Confidence: 0.7702043

00:32:04.060 --> 00:32:06.260 and therapeutic options including

NOTE Confidence: 0.7702043

00:32:06.260 --> 00:32:08.460 a current treatment paradigms,

NOTE Confidence: 0.7702043

00:32:08.460 --> 00:32:11.220 ongoing clinical trials and

NOTE Confidence: 0.7702043

00:32:11.220 --> 00:32:12.600 future directions.
NOTE Confidence: 0.7702043

00:32:12.600 --> 00:32:16.611 So let's start with the classification under
NOTE Confidence: 0.7702043

00:32:16.611 --> 00:32:20.677 the revised 2016 W 2 classification post.
NOTE Confidence: 0.7702043

00:32:20.680 --> 00:32:22.408 Transplant lymphoproliferative disorder
NOTE Confidence: 0.7702043

00:32:22.408 --> 00:32:25.864 are classified under the immune deficiency.
NOTE Confidence: 0.7702043

00:32:25.870 --> 00:32:27.658 Associated lymphoproliferative disorders,
NOTE Confidence: 0.7702043

00:32:27.658 --> 00:32:30.042 along with lymphoproliferative diseases
NOTE Confidence: 0.7702043

00:32:30.042 --> 00:32:32.799 associated with primary immune disorder,
NOTE Confidence: 0.7702043

00:32:32.800 --> 00:32:35.660 HIV infection and other
NOTE Confidence: 0.7702043

00:32:35.660 --> 00:32:37.090 iatrogenic immunodeficiency.
NOTE Confidence: 0.7702043

00:32:37.090 --> 00:32:40.247 Um, by definition they are any lymphoid
NOTE Confidence: 0.7702043

00:32:40.247 --> 00:32:42.531 or plasmacytic proliferation that develop
NOTE Confidence: 0.7702043

00:32:42.531 --> 00:32:45.117 as a consequence of immuno suppression.
NOTE Confidence: 0.7702043

00:32:45.120 --> 00:32:47.502 In order sequence of a solid
NOTE Confidence: 0.7702043

00:32:47.502 --> 00:32:50.020 organ or stem cell allograft,
NOTE Confidence: 0.7702043

00:32:50.020 --> 00:32:52.204 it is considered officiality.

NOTE Confidence: 0.7702043

00:32:52.204 --> 00:32:55.480 And based on the new classification,

NOTE Confidence: 0.7702043

00:32:55.480 --> 00:32:57.348 the device classification detailed

NOTE Confidence: 0.7702043

00:32:57.348 --> 00:32:58.749 include nondestructive PTL.

NOTE Confidence: 0.7702043

00:32:58.750 --> 00:33:00.154 These further subclassified

NOTE Confidence: 0.7702043

00:33:00.154 --> 00:33:01.558 into plasmacytic hyperplasia.

NOTE Confidence: 0.7702043

00:33:01.560 --> 00:33:04.160 Infectious modern closes like and

NOTE Confidence: 0.7702043

00:33:04.160 --> 00:33:06.760 Florida follicular pleasure which is

NOTE Confidence: 0.7702043

00:33:06.842 --> 00:33:09.516 a new entity under the new revision,

NOTE Confidence: 0.7702043

00:33:09.520 --> 00:33:11.544 polymorphic deity monomorphic TLD

NOTE Confidence: 0.7702043

00:33:11.544 --> 00:33:15.141 that comes into the B cell neoplasm

NOTE Confidence: 0.7702043

00:33:15.141 --> 00:33:18.445 and T cell nail Plaza and the

NOTE Confidence: 0.7702043

00:33:18.445 --> 00:33:20.240 classical Hodgkin lymphoma.

NOTE Confidence: 0.7702043

00:33:20.240 --> 00:33:21.638 So purely nondestructive,

NOTE Confidence: 0.7702043

00:33:21.638 --> 00:33:23.968 these diseases are classified based

NOTE Confidence: 0.7702043

00:33:23.968 --> 00:33:27.599 on the is the is the pathology major

NOTE Confidence: 0.7702043

00:33:27.599 --> 00:33:29.351 findings and undersell prevalence.
NOTE Confidence: 0.7702043

00:33:29.360 --> 00:33:31.180 There is usually preservation
NOTE Confidence: 0.7702043

00:33:31.180 --> 00:33:32.545 of the architecture,
NOTE Confidence: 0.7702043

00:33:32.550 --> 00:33:35.232 and these are polyclonal B cell
NOTE Confidence: 0.7702043

00:33:35.232 --> 00:33:36.573 proliferation by immunophenotyping
NOTE Confidence: 0.7702043

00:33:36.573 --> 00:33:37.570 genetic studies.
NOTE Confidence: 0.7702043

00:33:37.570 --> 00:33:40.390 There typically be positive the
NOTE Confidence: 0.7702043

00:33:40.390 --> 00:33:42.646 responsive to MENA suppression
NOTE Confidence: 0.7702043

00:33:42.646 --> 00:33:45.450 reduction in most of the cases and
NOTE Confidence: 0.7702043

00:33:45.450 --> 00:33:47.599 they are usually seen in kids.
NOTE Confidence: 0.7702043

00:33:47.600 --> 00:33:50.250 So in the pediatric population.
NOTE Confidence: 0.7702043

00:33:50.250 --> 00:33:53.094 So we do see on the bottom an example
NOTE Confidence: 0.7702043

00:33:53.094 --> 00:33:55.766 of plasmacytic hyperplasia with the
NOTE Confidence: 0.7702043

00:33:55.766 --> 00:33:58.042 preservation of the architecture
NOTE Confidence: 0.7702043

00:33:58.042 --> 00:34:01.312 of the lymph node and infiltrates
NOTE Confidence: 0.7702043

00:34:01.312 --> 00:34:04.282 of abundant plasma cells. Peter D.

NOTE Confidence: 0.7702043

00:34:04.282 --> 00:34:07.018 Polymorphic this is an entity that

NOTE Confidence: 0.7702043

00:34:07.018 --> 00:34:09.686 is characterized by either a genius

NOTE Confidence: 0.7702043

00:34:09.686 --> 00:34:11.776 mix of immunoblastic plasma cell

NOTE Confidence: 0.7702043

00:34:11.776 --> 00:34:14.334 and different size. The lymphocytes.

NOTE Confidence: 0.7702043

00:34:14.334 --> 00:34:16.619 The architectural is the architecture

NOTE Confidence: 0.7702043

00:34:16.619 --> 00:34:17.990 is usually faced.

NOTE Confidence: 0.7702043

00:34:17.990 --> 00:34:20.205 These are mostly polyclonal but

NOTE Confidence: 0.7702043

00:34:20.205 --> 00:34:22.964 presence of monoclonal B cell have

NOTE Confidence: 0.7702043

00:34:22.964 --> 00:34:25.289 been described and detected by

NOTE Confidence: 0.7702043

00:34:25.289 --> 00:34:27.590 immuno phenotype and genetic tool.

NOTE Confidence: 0.7702043

00:34:27.590 --> 00:34:29.765 There mostly EBV positive and

NOTE Confidence: 0.7702043

00:34:29.765 --> 00:34:32.620 some of them have been sealed.

NOTE Confidence: 0.7702043

00:34:32.620 --> 00:34:34.129 Six somatic hypermutation.

NOTE Confidence: 0.7702043

00:34:34.129 --> 00:34:36.644 So here's an example of

NOTE Confidence: 0.7702043

00:34:36.644 --> 00:34:38.528 architectural effacement on the left,

NOTE Confidence: 0.7702043

00:34:38.530 --> 00:34:41.057 with the associated to a large area
NOTE Confidence: 0.7702043

00:34:41.057 --> 00:34:44.014 of necrosis and on the right variable
NOTE Confidence: 0.7702043

00:34:44.014 --> 00:34:46.259 size and shape lymphoid infiltrate.
NOTE Confidence: 0.80955

00:34:48.510 --> 00:34:50.784 Monomorphic PTSD, those are the one
NOTE Confidence: 0.80955

00:34:50.784 --> 00:34:53.708 that do fulfill the criteria for non
NOTE Confidence: 0.80955

00:34:53.708 --> 00:34:56.372 Hodgkin lymphoma or plasma cell neoplasm,
NOTE Confidence: 0.80955

00:34:56.380 --> 00:34:59.082 small B cell lymphoma are not considered
NOTE Confidence: 0.80955

00:34:59.082 --> 00:35:01.760 at not the designated as PTLT,
NOTE Confidence: 0.80955

00:35:01.760 --> 00:35:04.686 with the exception of the beaded positive
NOTE Confidence: 0.80955

00:35:04.686 --> 00:35:06.854 extranodal marginal zone lymphoma that
NOTE Confidence: 0.80955

00:35:06.854 --> 00:35:09.398 usually arise in the cutaneous or
NOTE Confidence: 0.80955

00:35:09.398 --> 00:35:11.859 subcutaneous tissue and this is because
NOTE Confidence: 0.80955

00:35:11.859 --> 00:35:13.403 their standardized incidence ratio
NOTE Confidence: 0.80955

00:35:13.403 --> 00:35:16.325 is not different than in the regular
NOTE Confidence: 0.80955

00:35:16.325 --> 00:35:19.209 population and they're not started to happen.
NOTE Confidence: 0.80955

00:35:19.210 --> 00:35:21.765 As a consequence of the immune suppression,

NOTE Confidence: 0.80955

00:35:21.770 --> 00:35:24.826 besides those any other kind of non Hodgkin

NOTE Confidence: 0.80955

00:35:24.826 --> 00:35:27.330 lymphoma is considered upcity ality.

NOTE Confidence: 0.80955

00:35:27.330 --> 00:35:28.910 So the architecture defacement

NOTE Confidence: 0.80955

00:35:28.910 --> 00:35:30.095 is usually present.

NOTE Confidence: 0.80955

00:35:30.100 --> 00:35:32.025 Immuno, phenotypic and genetic features

NOTE Confidence: 0.80955

00:35:32.025 --> 00:35:34.415 are typically recapitulating what we do

NOTE Confidence: 0.80955

00:35:34.415 --> 00:35:36.039 see individual competent counterpart.

NOTE Confidence: 0.80955

00:35:36.040 --> 00:35:39.376 And here I included an example

NOTE Confidence: 0.80955

00:35:39.376 --> 00:35:41.600 on the left of.

NOTE Confidence: 0.80955

00:35:41.600 --> 00:35:45.008 You should be selling for infiltrating.

NOTE Confidence: 0.80955

00:35:45.010 --> 00:35:47.480 Lymph node and underwrite dereza.

NOTE Confidence: 0.80955

00:35:47.480 --> 00:35:48.416 An example.

NOTE Confidence: 0.80955

00:35:48.416 --> 00:35:52.160 This is a renal allograft biopsy with the

NOTE Confidence: 0.80955

00:35:52.255 --> 00:35:55.874 showing about this planning T cell gamma,

NOTE Confidence: 0.80955

00:35:55.880 --> 00:35:56.455 Delta,

NOTE Confidence: 0.80955

00:35:56.455 --> 00:35:59.905 T cell lymphoma with the characteristic
NOTE Confidence: 0.80955

00:35:59.905 --> 00:36:03.460 infiltration of the small blood vessels.
NOTE Confidence: 0.80955

00:36:03.460 --> 00:36:03.957 Finally,
NOTE Confidence: 0.80955

00:36:03.957 --> 00:36:05.945 classical Hodgkin lymphoma has
NOTE Confidence: 0.80955

00:36:05.945 --> 00:36:08.430 also been associated and described
NOTE Confidence: 0.80955

00:36:08.500 --> 00:36:10.672 in the setting of post transplant
NOTE Confidence: 0.80955

00:36:10.672 --> 00:36:12.799 and is considered to be APTLD.
NOTE Confidence: 0.80955

00:36:12.800 --> 00:36:15.272 It fulfills the criteria for the
NOTE Confidence: 0.80955

00:36:15.272 --> 00:36:17.948 high school informing that we do
NOTE Confidence: 0.80955

00:36:17.948 --> 00:36:19.856 see and immunocompetent population,
NOTE Confidence: 0.80955

00:36:19.860 --> 00:36:22.060 but is typically mixed cellularity.
NOTE Confidence: 0.80955

00:36:22.060 --> 00:36:24.490 It's always EBV positive and we
NOTE Confidence: 0.80955

00:36:24.490 --> 00:36:27.185 do see that predominantly in the
NOTE Confidence: 0.80955

00:36:27.185 --> 00:36:28.679 renal transplant recipients.
NOTE Confidence: 0.80955

00:36:28.680 --> 00:36:31.300 Therapies treated like the Hodgkin
NOTE Confidence: 0.80955

00:36:31.300 --> 00:36:33.920 lymphoma and immuno competent counterpart

NOTE Confidence: 0.80955

00:36:33.990 --> 00:36:36.606 and here an example of a release time.

NOTE Confidence: 0.80955

00:36:36.610 --> 00:36:38.920 Excel on the bottom surrounded

NOTE Confidence: 0.80955

00:36:38.920 --> 00:36:41.230 by an inflammatory background of

NOTE Confidence: 0.80955

00:36:41.312 --> 00:36:43.587 lymphocytes and using a fields.

NOTE Confidence: 0.80955

00:36:43.590 --> 00:36:46.579 And this is our typical greatest number

NOTE Confidence: 0.80955

00:36:46.579 --> 00:36:50.079 Excel with the city 20 CD 30 positive ITI.

NOTE Confidence: 0.80955

00:36:50.080 --> 00:36:53.456 So very very Inter genius group of diseases.

NOTE Confidence: 0.80955

00:36:53.460 --> 00:36:55.005 And so how?

NOTE Confidence: 0.80955

00:36:55.005 --> 00:36:58.095 How frequently are our diesel informers?

NOTE Confidence: 0.80955

00:36:58.100 --> 00:37:00.194 So we do about 40,000 transplant

NOTE Confidence: 0.80955

00:37:00.194 --> 00:37:02.936 every year in the United States and

NOTE Confidence: 0.80955

00:37:02.936 --> 00:37:05.486 period is the second most common

NOTE Confidence: 0.80955

00:37:05.486 --> 00:37:07.769 malignancy in this patient population

NOTE Confidence: 0.80955

00:37:07.769 --> 00:37:09.960 behind non Melanoma skin cancer.

NOTE Confidence: 0.80955

00:37:09.960 --> 00:37:13.233 So it accounts for 21% of all the

NOTE Confidence: 0.80955

00:37:13.233 --> 00:37:15.798 cancers in recipients of solid organ
NOTE Confidence: 0.80955

00:37:15.798 --> 00:37:18.300 transplant as compared to only four
NOTE Confidence: 0.80955

00:37:18.300 --> 00:37:21.000 to 5% of the cancers and immuno
NOTE Confidence: 0.80955

00:37:21.000 --> 00:37:21.816 competent population.
NOTE Confidence: 0.80955

00:37:21.820 --> 00:37:24.020 The incidence has increased over
NOTE Confidence: 0.80955

00:37:24.020 --> 00:37:27.029 the past two decades and this is
NOTE Confidence: 0.80955

00:37:27.029 --> 00:37:28.849 for a variety of reasons.
NOTE Confidence: 0.80955

00:37:28.850 --> 00:37:31.475 The increased age at the older age
NOTE Confidence: 0.80955

00:37:31.475 --> 00:37:35.468 of the Gilded Age of and owner and
NOTE Confidence: 0.80955

00:37:35.468 --> 00:37:37.692 recipients new immunosuppressive treatment.
NOTE Confidence: 0.80955

00:37:37.700 --> 00:37:40.730 The introduction of the haploidentical stem
NOTE Confidence: 0.80955

00:37:40.730 --> 00:37:43.309 cell transplant and improved awareness
NOTE Confidence: 0.80955

00:37:43.309 --> 00:37:46.195 of the disease and diagnostic schools.
NOTE Confidence: 0.80955

00:37:46.200 --> 00:37:49.026 So after a solid organ transplant,
NOTE Confidence: 0.80955

00:37:49.030 --> 00:37:51.856 the risk of developing a PLD
NOTE Confidence: 0.80955

00:37:51.856 --> 00:37:54.674 varies for over 20% two point,

NOTE Confidence: 0.80955
00:37:54.674 --> 00:37:57.476 8% depending on the organ transplanted
NOTE Confidence: 0.80955
00:37:57.476 --> 00:37:59.888 multi visceral intestinal being associated
NOTE Confidence: 0.80955
00:37:59.888 --> 00:38:03.157 with a higher risk followed by lung,
NOTE Confidence: 0.80955
00:38:03.160 --> 00:38:03.617 heart,
NOTE Confidence: 0.80955
00:38:03.617 --> 00:38:04.074 liver,
NOTE Confidence: 0.80955
00:38:04.074 --> 00:38:06.359 pancreas and with kidney being
NOTE Confidence: 0.80955
00:38:06.359 --> 00:38:09.238 the carrying the lower risk for
NOTE Confidence: 0.80955
00:38:09.238 --> 00:38:11.623 multiple attic stem cell transplant.
NOTE Confidence: 0.80955
00:38:11.630 --> 00:38:14.306 The risks varies based on the
NOTE Confidence: 0.80955
00:38:14.306 --> 00:38:17.430 HLA degree of the HLA matching.
NOTE Confidence: 0.80955
00:38:17.430 --> 00:38:21.282 And the and the need for T cell depletion.
NOTE Confidence: 0.80955
00:38:21.290 --> 00:38:24.570 So it is a highest for upload denticle
NOTE Confidence: 0.80955
00:38:24.570 --> 00:38:27.724 without this addition 20% and it goes
NOTE Confidence: 0.80955
00:38:27.724 --> 00:38:30.730 down to 3% in recipients of matched
NOTE Confidence: 0.80955
00:38:30.730 --> 00:38:32.450 related dollar hematopoetic stem
NOTE Confidence: 0.73817724

00:38:32.450 --> 00:38:35.975 cell transplant. So what do we know
NOTE Confidence: 0.73817724

00:38:35.975 --> 00:38:38.080 in terms of risk factors besides
NOTE Confidence: 0.73817724

00:38:38.080 --> 00:38:41.174 the type of the transplant of the
NOTE Confidence: 0.73817724

00:38:41.174 --> 00:38:43.873 transplanted organ or the type of
NOTE Confidence: 0.73817724

00:38:43.873 --> 00:38:45.605 allogeneic stem cell transplant?
NOTE Confidence: 0.73817724

00:38:45.610 --> 00:38:48.088 For recipients of solid organ transplant,
NOTE Confidence: 0.73817724

00:38:48.090 --> 00:38:50.568 it is an established risk factor.
NOTE Confidence: 0.73817724

00:38:50.570 --> 00:38:51.882 The degree of Mr.
NOTE Confidence: 0.73817724

00:38:51.882 --> 00:38:54.399 EBV mismatch at the time of transplantation
NOTE Confidence: 0.73817724

00:38:54.399 --> 00:38:57.201 with the recipients being a big
NOTE Confidence: 0.73817724

00:38:57.201 --> 00:39:00.068 negative and the donor EBV positive.
NOTE Confidence: 0.73817724

00:39:00.070 --> 00:39:02.536 Also, the intensity of the induction,
NOTE Confidence: 0.73817724

00:39:02.540 --> 00:39:02.952 immunosuppression,
NOTE Confidence: 0.73817724

00:39:02.952 --> 00:39:04.600 treatment and duration of
NOTE Confidence: 0.73817724

00:39:04.600 --> 00:39:05.424 maintenance therapy,
NOTE Confidence: 0.73817724

00:39:05.430 --> 00:39:07.395 including increased the need of

NOTE Confidence: 0.73817724

00:39:07.395 --> 00:39:09.980 treatment due to graft rejection episodes.

NOTE Confidence: 0.73817724

00:39:09.980 --> 00:39:11.650 There is a strong evidence

NOTE Confidence: 0.73817724

00:39:11.650 --> 00:39:13.320 associated with the use of

NOTE Confidence: 0.73817724

00:39:13.392 --> 00:39:15.348 certain immunosuppressive drug.

NOTE Confidence: 0.8300465

00:39:17.670 --> 00:39:20.778 And in contact with others that

NOTE Confidence: 0.8300465

00:39:20.778 --> 00:39:23.420 are less associated and weak,

NOTE Confidence: 0.8300465

00:39:23.420 --> 00:39:25.955 evidence of risk is associated

NOTE Confidence: 0.8300465

00:39:25.955 --> 00:39:27.983 with infectious diseases and

NOTE Confidence: 0.8300465

00:39:27.983 --> 00:39:30.747 non EBV infection for instance,

NOTE Confidence: 0.8300465

00:39:30.750 --> 00:39:32.361 and other characteristics,

NOTE Confidence: 0.8300465

00:39:32.361 --> 00:39:33.972 genetic characteristics or

NOTE Confidence: 0.8300465

00:39:33.972 --> 00:39:36.500 underlying comorbidities of the host.

NOTE Confidence: 0.8300465

00:39:36.500 --> 00:39:38.069 For hematopoietic stem

NOTE Confidence: 0.8300465

00:39:38.069 --> 00:39:39.638 cell transplant recipient,

NOTE Confidence: 0.8300465

00:39:39.640 --> 00:39:43.091 age seems to be the biggest risk

NOTE Confidence: 0.8300465

00:39:43.091 --> 00:39:45.828 factor for development of these
NOTE Confidence: 0.8300465

00:39:45.828 --> 00:39:48.160 diseases and the conditioning.
NOTE Confidence: 0.8300465

00:39:48.160 --> 00:39:53.720 Regiment. Um also, um.
NOTE Confidence: 0.8300465

00:39:53.720 --> 00:39:55.900 So in terms of timing,
NOTE Confidence: 0.8300465

00:39:55.900 --> 00:39:58.115 typically PTSD arrives early in
NOTE Confidence: 0.8300465

00:39:58.115 --> 00:40:00.330 the setting of hematopoietic stem.
NOTE Confidence: 0.8300465

00:40:00.330 --> 00:40:02.622 The transplant and leader in the
NOTE Confidence: 0.8300465

00:40:02.622 --> 00:40:05.500 setting of a solid organ transplant,
NOTE Confidence: 0.8300465

00:40:05.500 --> 00:40:08.086 but it's not really that predictable.
NOTE Confidence: 0.8300465

00:40:08.090 --> 00:40:10.904 We considered an early onset if the
NOTE Confidence: 0.8300465

00:40:10.904 --> 00:40:13.999 PTSD arise in the first year after
NOTE Confidence: 0.8300465

00:40:13.999 --> 00:40:16.705 the transplant and the late onset,
NOTE Confidence: 0.8300465

00:40:16.710 --> 00:40:19.290 if it arises a year later.
NOTE Confidence: 0.8300465

00:40:19.290 --> 00:40:24.197 Starting one year after the transplant and.
NOTE Confidence: 0.8300465

00:40:24.200 --> 00:40:26.280 And the reason the battle,
NOTE Confidence: 0.8300465

00:40:26.280 --> 00:40:28.860 the pathogenesis is associated in the

NOTE Confidence: 0.8300465

00:40:28.860 --> 00:40:31.910 early onset to an acute EBV infection

NOTE Confidence: 0.8300465

00:40:31.910 --> 00:40:34.815 or a reactivation of the virus in

NOTE Confidence: 0.8300465

00:40:34.893 --> 00:40:37.574 the setting of a reduction of the

NOTE Confidence: 0.8300465

00:40:37.574 --> 00:40:39.560 MTV cytotoxic T cell lymphocytes,

NOTE Confidence: 0.8300465

00:40:39.560 --> 00:40:41.220 usually early PTLDREB positive,

NOTE Confidence: 0.8300465

00:40:41.220 --> 00:40:43.800 and frequently there is the

NOTE Confidence: 0.8300465

00:40:43.800 --> 00:40:45.348 allograft is involved.

NOTE Confidence: 0.8300465

00:40:45.350 --> 00:40:48.626 In the late onset there have been

NOTE Confidence: 0.8300465

00:40:48.626 --> 00:40:51.200 many hypothesis so hidden around

NOTE Confidence: 0.8300465

00:40:51.200 --> 00:40:53.900 the infection with the baby,

NOTE Confidence: 0.8300465

00:40:53.900 --> 00:40:56.725 then resolved and lymphoma keeps

NOTE Confidence: 0.8300465

00:40:56.725 --> 00:40:58.985 developing other viruses besides

NOTE Confidence: 0.8300465

00:40:58.985 --> 00:41:01.365 BV has been hypothesized as

NOTE Confidence: 0.8300465

00:41:01.365 --> 00:41:03.957 playing a role such as CMV,

NOTE Confidence: 0.8300465

00:41:03.960 --> 00:41:06.044 a persistent antigenic stimulation

NOTE Confidence: 0.8300465

00:41:06.044 --> 00:41:09.170 done by the allograft and lymphocyte
NOTE Confidence: 0.8300465

00:41:09.247 --> 00:41:12.109 deregulation in the setting of a
NOTE Confidence: 0.8300465

00:41:12.109 --> 00:41:14.017 chronic immuno suppressed state.
NOTE Confidence: 0.8300465

00:41:14.020 --> 00:41:15.808 These are usually.
NOTE Confidence: 0.8300465

00:41:15.808 --> 00:41:17.000 More likely,
NOTE Confidence: 0.8300465

00:41:17.000 --> 00:41:19.330 extra node with Extranodal involvement,
NOTE Confidence: 0.8300465

00:41:19.330 --> 00:41:21.181 not necessarily involving
NOTE Confidence: 0.8300465

00:41:21.181 --> 00:41:24.266 the graft and the monomorphic
NOTE Confidence: 0.8300465

00:41:24.266 --> 00:41:27.088 subtype is the most common.
NOTE Confidence: 0.8300465

00:41:27.090 --> 00:41:29.394 So what do we know about the prognosis
NOTE Confidence: 0.8300465

00:41:29.394 --> 00:41:31.820 of this disease that are regarding
NOTE Confidence: 0.8300465

00:41:31.820 --> 00:41:34.045 prognosis are mostly from single
NOTE Confidence: 0.8300465

00:41:34.045 --> 00:41:35.800 institution retrospective analysis and
NOTE Confidence: 0.8300465

00:41:35.800 --> 00:41:38.284 during my time at Columbia University
NOTE Confidence: 0.8300465

00:41:38.284 --> 00:41:40.800 I work on setting up a tumor bank
NOTE Confidence: 0.8300465

00:41:40.800 --> 00:41:42.773 for this disease with pathological

NOTE Confidence: 0.8300465
00:41:42.773 --> 00:41:45.278 specimen link to clinical information,
NOTE Confidence: 0.8300465
00:41:45.280 --> 00:41:47.905 and this is what we have learned
NOTE Confidence: 0.8300465
00:41:47.905 --> 00:41:50.309 from the analysis of 120 patients.
NOTE Confidence: 0.8300465
00:41:50.310 --> 00:41:52.368 This is the largest series published
NOTE Confidence: 0.8300465
00:41:52.368 --> 00:41:54.949 so far on this specific disease.
NOTE Confidence: 0.8300465
00:41:54.950 --> 00:41:55.374 Interestingly,
NOTE Confidence: 0.8300465
00:41:55.374 --> 00:41:57.070 most of the clinical.
NOTE Confidence: 0.8300465
00:41:57.070 --> 00:41:59.180 Features that we think might
NOTE Confidence: 0.8300465
00:41:59.180 --> 00:42:01.784 predict an outcome might have an
NOTE Confidence: 0.8300465
00:42:01.784 --> 00:42:03.849 impact on the overall survival.
NOTE Confidence: 0.8300465
00:42:03.850 --> 00:42:05.970 Did not correlate with overall
NOTE Confidence: 0.8300465
00:42:05.970 --> 00:42:08.090 survival in our patient population,
NOTE Confidence: 0.8300465
00:42:08.090 --> 00:42:10.640 including the subtype of the PTSD,
NOTE Confidence: 0.8300465
00:42:10.640 --> 00:42:13.510 the decade of diagnosis prior or after
NOTE Confidence: 0.8300465
00:42:13.510 --> 00:42:15.729 the introduction of their attack.
NOTE Confidence: 0.8300465

00:42:15.730 --> 00:42:18.691 Some organ do kind of organ transplanted
NOTE Confidence: 0.8300465

00:42:18.691 --> 00:42:20.388 DV status, graft involvement,
NOTE Confidence: 0.8300465

00:42:20.388 --> 00:42:21.660 and extranodal involvement
NOTE Confidence: 0.8300465

00:42:21.660 --> 00:42:23.356 or stage of diagnosis.
NOTE Confidence: 0.8300465

00:42:23.360 --> 00:42:25.898 So using a recursive partitioning model,
NOTE Confidence: 0.8300465

00:42:25.900 --> 00:42:28.450 we separated patient.
NOTE Confidence: 0.8300465

00:42:28.450 --> 00:42:28.799 Recursively,
NOTE Confidence: 0.8300465

00:42:28.799 --> 00:42:30.893 at each step into two distinct
NOTE Confidence: 0.8300465

00:42:30.893 --> 00:42:33.208 groups based on the variables that
NOTE Confidence: 0.8300465

00:42:33.208 --> 00:42:35.218 provided the maximal separation based
NOTE Confidence: 0.8300465

00:42:35.218 --> 00:42:37.327 on survival and using this model,
NOTE Confidence: 0.8300465

00:42:37.330 --> 00:42:39.458 we were able to identify based on
NOTE Confidence: 0.8300465

00:42:39.458 --> 00:42:42.221 age CD 20 expression and equal status
NOTE Confidence: 0.8300465

00:42:42.221 --> 00:42:44.891 for groups that were well separated
NOTE Confidence: 0.8300465

00:42:44.966 --> 00:42:47.388 in terms of roll survival and with
NOTE Confidence: 0.8300465

00:42:47.388 --> 00:42:50.005 an even number of patient and in the

NOTE Confidence: 0.8300465

00:42:50.005 --> 00:42:52.513 lowest group we can see that the

NOTE Confidence: 0.8300465

00:42:52.513 --> 00:42:55.087 medium overall survival was not reached.

NOTE Confidence: 0.8300465

00:42:55.090 --> 00:42:57.045 Those were essentially mostly pediatric

NOTE Confidence: 0.8300465

00:42:57.045 --> 00:42:59.440 patients with a good performance status.

NOTE Confidence: 0.8300465

00:42:59.440 --> 00:43:01.680 What is in the very high risk group

NOTE Confidence: 0.8300465

00:43:01.680 --> 00:43:03.969 elderly with a foot Burma status and

NOTE Confidence: 0.8300465

00:43:03.969 --> 00:43:05.634 essentially all patients with the

NOTE Confidence: 0.8097424

00:43:05.695 --> 00:43:07.115 CD? Twenty negative disease,

NOTE Confidence: 0.8097424

00:43:07.115 --> 00:43:09.190 the median overall survival was

NOTE Confidence: 0.8097424

00:43:09.190 --> 00:43:11.490 as short as one point 3 months.

NOTE Confidence: 0.8097424

00:43:11.490 --> 00:43:14.190 So what else we have learned,

NOTE Confidence: 0.8097424

00:43:14.190 --> 00:43:16.702 we know very well that T cell lymphoma

NOTE Confidence: 0.8097424

00:43:16.702 --> 00:43:20.457 have a much worse prognosis than Bissell

NOTE Confidence: 0.8097424

00:43:20.457 --> 00:43:22.290 informal immunocompetent population.

NOTE Confidence: 0.8097424

00:43:22.290 --> 00:43:24.696 But what are?

NOTE Confidence: 0.8097424

00:43:24.696 --> 00:43:27.202 What is the behavior of this LPT?
NOTE Confidence: 0.8097424

00:43:27.210 --> 00:43:29.010 LD is not well, no,
NOTE Confidence: 0.8097424

00:43:29.010 --> 00:43:31.874 not due to the rarity of these diseases.
NOTE Confidence: 0.8097424

00:43:31.880 --> 00:43:34.440 So we did analyze in our series of
NOTE Confidence: 0.8097424

00:43:34.440 --> 00:43:36.729 pulling over monomorphic PTSD and the
NOTE Confidence: 0.8097424

00:43:36.729 --> 00:43:39.779 differences between B cells and T cell TLD.
NOTE Confidence: 0.8097424

00:43:39.780 --> 00:43:42.316 And we do see that they sort of
NOTE Confidence: 0.8097424

00:43:42.316 --> 00:43:44.424 recapitulate what we do see and
NOTE Confidence: 0.8097424

00:43:44.424 --> 00:43:45.824 immuno competent counterpart in
NOTE Confidence: 0.8097424

00:43:45.824 --> 00:43:48.172 terms of prognosis with the median
NOTE Confidence: 0.8097424

00:43:48.172 --> 00:43:50.147 overall survival being very low
NOTE Confidence: 0.8097424

00:43:50.147 --> 00:43:52.932 for the T cell and compared to
NOTE Confidence: 0.8097424

00:43:52.932 --> 00:43:54.910 the diesel in monomorphic PLD.
NOTE Confidence: 0.8097424

00:43:54.910 --> 00:43:57.339 Also, we did observe that the time
NOTE Confidence: 0.8097424

00:43:57.339 --> 00:44:00.047 of the median time to answer it was
NOTE Confidence: 0.8097424

00:44:00.047 --> 00:44:02.421 much longer for T cell nine years

NOTE Confidence: 0.8097424

00:44:02.421 --> 00:44:04.899 compared to three years for the B

NOTE Confidence: 0.8097424

00:44:04.899 --> 00:44:07.969 cell type and all T cell period in

NOTE Confidence: 0.8097424

00:44:07.969 --> 00:44:10.689 our series were leaving negative.

NOTE Confidence: 0.8097424

00:44:10.690 --> 00:44:13.539 Another thing that that we we have

NOTE Confidence: 0.8097424

00:44:13.539 --> 00:44:16.775 also learned is that importance of more

NOTE Confidence: 0.8097424

00:44:16.775 --> 00:44:19.661 marrow of staging and the incidents

NOTE Confidence: 0.8097424

00:44:19.746 --> 00:44:22.518 of more involvement in the in PLD.

NOTE Confidence: 0.8097424

00:44:22.520 --> 00:44:26.056 It is very common in our series of

NOTE Confidence: 0.8097424

00:44:26.056 --> 00:44:28.920 patients at 23% of monomorphic PLD

NOTE Confidence: 0.8097424

00:44:28.920 --> 00:44:31.570 had bone marrow involvement compared

NOTE Confidence: 0.8097424

00:44:31.570 --> 00:44:35.030 in the in the T cell subtypes 50%.

NOTE Confidence: 0.8097424

00:44:35.030 --> 00:44:35.514 Also,

NOTE Confidence: 0.8097424

00:44:35.514 --> 00:44:37.450 polymorphic exhibited our very

NOTE Confidence: 0.8097424

00:44:37.450 --> 00:44:39.386 high bone marrow involvement.

NOTE Confidence: 0.8097424

00:44:39.390 --> 00:44:42.393 15.7 All the cases of polymorphic with

NOTE Confidence: 0.8097424

00:44:42.393 --> 00:44:45.679 where bone marrow involvement was detected.

NOTE Confidence: 0.8097424

00:44:45.680 --> 00:44:50.880 This resulted in up stage of the disease.

NOTE Confidence: 0.8097424

00:44:50.880 --> 00:44:52.468 And ever involvement was

NOTE Confidence: 0.8097424

00:44:52.468 --> 00:44:54.056 associated with poorer outcome.

NOTE Confidence: 0.8097424

00:44:54.060 --> 00:44:56.538 So we did compare the incidence of

NOTE Confidence: 0.8097424

00:44:56.538 --> 00:44:58.609 the involvement of Lombardy Boomer

NOTE Confidence: 0.8097424

00:44:58.609 --> 00:45:00.949 involvement in monomorphic PTSD compared

NOTE Confidence: 0.8097424

00:45:00.949 --> 00:45:03.840 to the normal diffuse large B cell

NOTE Confidence: 0.8097424

00:45:03.840 --> 00:45:06.376 lymphoma and HIV diffuse large B cell

NOTE Confidence: 0.8097424

00:45:06.376 --> 00:45:08.000 lymphoma patients diagnosed during

NOTE Confidence: 0.8097424

00:45:08.000 --> 00:45:10.857 the same time frame at our institution

NOTE Confidence: 0.8097424

00:45:10.857 --> 00:45:13.503 and we do see here that monomorphic,

NOTE Confidence: 0.8097424

00:45:13.510 --> 00:45:15.102 detailed involvement compared to

NOTE Confidence: 0.8097424

00:45:15.102 --> 00:45:17.490 the HIV positive diffuse large B

NOTE Confidence: 0.8097424

00:45:17.560 --> 00:45:19.990 cell involvement and this is suggest

NOTE Confidence: 0.8097424

00:45:19.990 --> 00:45:21.610 that that immuno compromised.

NOTE Confidence: 0.8097424

00:45:21.610 --> 00:45:24.006 State regardless of videology

NOTE Confidence: 0.8097424

00:45:24.006 --> 00:45:27.001 vial associated or higher trajanic

NOTE Confidence: 0.8097424

00:45:27.001 --> 00:45:30.516 maybe is a major risk factor for

NOTE Confidence: 0.8097424

00:45:30.516 --> 00:45:32.400 dissemination to the marrow.

NOTE Confidence: 0.8097424

00:45:32.400 --> 00:45:33.090 Finally,

NOTE Confidence: 0.8097424

00:45:33.090 --> 00:45:35.850 this is a loser.

NOTE Confidence: 0.8097424

00:45:35.850 --> 00:45:37.957 Analyze last year actually two years ago

NOTE Confidence: 0.8097424

00:45:37.957 --> 00:45:40.346 and this was presented at ASH in 2019.

NOTE Confidence: 0.8097424

00:45:40.350 --> 00:45:42.432 We did analyze the data regarding

NOTE Confidence: 0.8097424

00:45:42.432 --> 00:45:44.954 the cell of origin and the impact

NOTE Confidence: 0.8097424

00:45:44.954 --> 00:45:47.078 of treatment on the outcome of

NOTE Confidence: 0.8097424

00:45:47.078 --> 00:45:48.968 diffuse large B cell lymphoma.

NOTE Confidence: 0.8097424

00:45:48.970 --> 00:45:51.455 So these type and in our series

NOTE Confidence: 0.8097424

00:45:51.455 --> 00:45:53.458 non germinal center was more

NOTE Confidence: 0.8097424

00:45:53.458 --> 00:45:55.178 common than germinal center.

NOTE Confidence: 0.8097424

00:45:55.180 --> 00:45:57.996 I just want to highlight here that as
NOTE Confidence: 0.8097424

00:45:57.996 --> 00:45:59.848 previously reported and non germinal
NOTE Confidence: 0.8097424

00:45:59.848 --> 00:46:02.002 center PTSD is usually be positive
NOTE Confidence: 0.8097424

00:46:02.002 --> 00:46:05.058 versus germinal center is usually it will
NOTE Confidence: 0.8097424

00:46:05.058 --> 00:46:06.814 be negative clinical characteristic,
NOTE Confidence: 0.8097424

00:46:06.820 --> 00:46:07.746 organ transplant,
NOTE Confidence: 0.8097424

00:46:07.746 --> 00:46:08.209 immunosuppressive,
NOTE Confidence: 0.8097424

00:46:08.209 --> 00:46:11.450 treatment time of onset was not different
NOTE Confidence: 0.8097424

00:46:11.518 --> 00:46:14.038 in these two subtypes and there is a
NOTE Confidence: 0.8097424

00:46:14.038 --> 00:46:15.740 trend suggesting a better outcome,
NOTE Confidence: 0.8097424

00:46:15.740 --> 00:46:19.060 a better PFS and OS in patients with.
NOTE Confidence: 0.8097424

00:46:19.060 --> 00:46:21.065 Germinal standard compared to non
NOTE Confidence: 0.8097424

00:46:21.065 --> 00:46:23.070 germinal center mirroring the outcome
NOTE Confidence: 0.8097424

00:46:23.128 --> 00:46:24.504 in Indiana competent population
NOTE Confidence: 0.8097424

00:46:24.504 --> 00:46:26.568 and RE broker did not improve
NOTE Confidence: 0.8097424

00:46:26.632 --> 00:46:28.440 overall survival or progression.

NOTE Confidence: 0.8097424

00:46:28.440 --> 00:46:29.856 Free survival were compared

NOTE Confidence: 0.8097424

00:46:29.856 --> 00:46:31.980 to R chop but in not

NOTE Confidence: 0.7767812

00:46:32.055 --> 00:46:34.617 resulted also either in an increase

NOTE Confidence: 0.7767812

00:46:34.617 --> 00:46:36.784 toxicity in our series was

NOTE Confidence: 0.7767812

00:46:36.784 --> 00:46:39.040 extremely low and only one patient

NOTE Confidence: 0.7767812

00:46:39.040 --> 00:46:42.540 died in each treatment group.

NOTE Confidence: 0.7767812

00:46:42.540 --> 00:46:44.927 So the current challenges for PT LDR

NOTE Confidence: 0.7767812

00:46:44.927 --> 00:46:47.418 that this is an uncommon disease,

NOTE Confidence: 0.7767812

00:46:47.420 --> 00:46:50.265 as we saw there is a bigot originality

NOTE Confidence: 0.7767812

00:46:50.265 --> 00:46:53.489 in in the type of PTSD that is it

NOTE Confidence: 0.7767812

00:46:53.489 --> 00:46:55.664 originality in the patient population,

NOTE Confidence: 0.7767812

00:46:55.670 --> 00:46:57.540 in the allograft or multiply

NOTE Confidence: 0.7767812

00:46:57.540 --> 00:46:59.036 attic stem cell transplant,

NOTE Confidence: 0.7767812

00:46:59.040 --> 00:47:00.716 and immunosuppressive treatment they

NOTE Confidence: 0.7767812

00:47:00.716 --> 00:47:03.643 receive that is a high mortality rate

NOTE Confidence: 0.7767812

00:47:03.643 --> 00:47:05.719 that is associated with the chemotherapy

NOTE Confidence: 0.7767812

00:47:05.719 --> 00:47:08.208 and this is usually in length to

NOTE Confidence: 0.7767812

00:47:08.208 --> 00:47:09.938 the increased risk of infection

NOTE Confidence: 0.7767812

00:47:09.938 --> 00:47:12.636 that we do see in these patients.

NOTE Confidence: 0.7767812

00:47:12.640 --> 00:47:15.316 Population and unique to this patient

NOTE Confidence: 0.7767812

00:47:15.316 --> 00:47:18.450 population is the risk of graft failure.

NOTE Confidence: 0.7767812

00:47:18.450 --> 00:47:23.280 So currently general principle of treatment

NOTE Confidence: 0.7767812

00:47:23.280 --> 00:47:25.695 include immunosuppression reduction.

NOTE Confidence: 0.7767812

00:47:25.700 --> 00:47:28.500 I just want to mention that the

NOTE Confidence: 0.7767812

00:47:28.500 --> 00:47:30.746 only perspective trial that utilize

NOTE Confidence: 0.7767812

00:47:30.746 --> 00:47:33.156 immuno suppression reduction as part

NOTE Confidence: 0.7767812

00:47:33.156 --> 00:47:35.836 of a sequential treatment for this

NOTE Confidence: 0.7767812

00:47:35.836 --> 00:47:38.531 disease on a very large sample of

NOTE Confidence: 0.7767812

00:47:38.540 --> 00:47:41.852 you know on a very large number of

NOTE Confidence: 0.7767812

00:47:41.852 --> 00:47:44.528 patients 160 patient showed a 40%

NOTE Confidence: 0.7767812

00:47:44.530 --> 00:47:46.670 incidence of acute graft reaction.

NOTE Confidence: 0.7767812

00:47:46.670 --> 00:47:49.556 So typical in the adult population

NOTE Confidence: 0.7767812

00:47:49.556 --> 00:47:50.518 immunosuppression reduction

NOTE Confidence: 0.7767812

00:47:50.518 --> 00:47:52.657 is utilized at the same time.

NOTE Confidence: 0.7767812

00:47:52.660 --> 00:47:54.532 Other interventions such as

NOTE Confidence: 0.7767812

00:47:54.532 --> 00:47:56.404 rituximab are or combination.

NOTE Confidence: 0.7767812

00:47:56.410 --> 00:47:58.386 Chemotherapy surgery, radiation therapy.

NOTE Confidence: 0.7767812

00:47:58.386 --> 00:47:58.880 Unlikely.

NOTE Confidence: 0.7767812

00:47:58.880 --> 00:48:02.144 What we do see in Hodgkin and an

NOTE Confidence: 0.7767812

00:48:02.144 --> 00:48:05.713 article in former is a well established

NOTE Confidence: 0.7767812

00:48:05.713 --> 00:48:09.230 the treatment for stage one disease,

NOTE Confidence: 0.7767812

00:48:09.230 --> 00:48:12.182 PTSD and in the relapsed and

NOTE Confidence: 0.7767812

00:48:12.182 --> 00:48:13.166 refractory setting.

NOTE Confidence: 0.7767812

00:48:13.170 --> 00:48:15.674 There are adoptive immunotherapy

NOTE Confidence: 0.7767812

00:48:15.674 --> 00:48:18.178 utilizing EBV specific cytotoxic

NOTE Confidence: 0.7767812

00:48:18.178 --> 00:48:21.653 T cells and high dose chemotherapy

NOTE Confidence: 0.7767812

00:48:21.653 --> 00:48:24.845 with a toddler stem cell transplant
NOTE Confidence: 0.7767812

00:48:24.935 --> 00:48:26.907 or both being explored.
NOTE Confidence: 0.7767812

00:48:26.910 --> 00:48:30.886 So there are only few prospective trials,
NOTE Confidence: 0.7767812

00:48:30.890 --> 00:48:33.170 primarily on polymorphic and
NOTE Confidence: 0.7767812

00:48:33.170 --> 00:48:36.622 monomorphic beissel. PTSD and hold the.
NOTE Confidence: 0.7767812

00:48:36.622 --> 00:48:38.934 Stop for trials here.
NOTE Confidence: 0.7767812

00:48:38.940 --> 00:48:39.310 Um,
NOTE Confidence: 0.7767812

00:48:39.310 --> 00:48:41.900 use their attack some as a single
NOTE Confidence: 0.7767812

00:48:41.900 --> 00:48:45.082 agent with a very high with a good
NOTE Confidence: 0.7767812

00:48:45.082 --> 00:48:47.589 overall response rate under an CR rate,
NOTE Confidence: 0.7767812

00:48:47.590 --> 00:48:49.290 but not exciting overall survival
NOTE Confidence: 0.7767812

00:48:49.290 --> 00:48:51.792 due to early relapse is the best
NOTE Confidence: 0.7767812

00:48:51.792 --> 00:48:53.642 results that have been achieved
NOTE Confidence: 0.7767812

00:48:53.642 --> 00:48:55.622 that utilizing either a sequential
NOTE Confidence: 0.7767812

00:48:55.622 --> 00:48:57.647 treatment or a risk stratifies
NOTE Confidence: 0.7767812

00:48:57.647 --> 00:48:59.830 sequential treatment and this is the

NOTE Confidence: 0.7767812

00:48:59.830 --> 00:49:02.070 PTL D1 trials that is the largest

NOTE Confidence: 0.7767812

00:49:02.143 --> 00:49:04.313 phase two trial ever conducted

NOTE Confidence: 0.7767812

00:49:04.313 --> 00:49:06.483 in this patient population and

NOTE Confidence: 0.7767812

00:49:06.554 --> 00:49:08.190 reported by the German.

NOTE Confidence: 0.7767812

00:49:08.190 --> 00:49:10.810 Study group so will review

NOTE Confidence: 0.7767812

00:49:10.810 --> 00:49:14.090 the results of the PD L D1.

NOTE Confidence: 0.7767812

00:49:14.090 --> 00:49:16.550 The risk stratified sequential treatment.

NOTE Confidence: 0.7767812

00:49:16.550 --> 00:49:21.485 This was published in JCO in 2017.

NOTE Confidence: 0.7767812

00:49:21.490 --> 00:49:23.608 Patients were with that newly diagnosis

NOTE Confidence: 0.7767812

00:49:23.608 --> 00:49:25.881 of PTSD received an induction treatment

NOTE Confidence: 0.7767812

00:49:25.881 --> 00:49:28.281 with rituximab and then based on

NOTE Confidence: 0.7767812

00:49:28.281 --> 00:49:30.317 their response they received the

NOTE Confidence: 0.7767812

00:49:30.317 --> 00:49:31.873 consolidation with rituximab alone

NOTE Confidence: 0.7767812

00:49:31.873 --> 00:49:34.580 or they were escalated to our CHOP

NOTE Confidence: 0.7767812

00:49:34.580 --> 00:49:36.890 and 152 patients were enrolled again.

NOTE Confidence: 0.7767812

00:49:36.890 --> 00:49:39.480 This is the largest study in this
NOTE Confidence: 0.7767812

00:49:39.480 --> 00:49:41.665 disease that has ever been conducted
NOTE Confidence: 0.7767812

00:49:41.665 --> 00:49:44.508 and we do still at 1/4 of them
NOTE Confidence: 0.7767812

00:49:44.508 --> 00:49:46.688 after the initial induction with
NOTE Confidence: 0.7767812

00:49:46.688 --> 00:49:49.640 maximum achieved a CR and these were
NOTE Confidence: 0.7767812

00:49:49.640 --> 00:49:52.040 the patient that did not receive.
NOTE Confidence: 0.7767812

00:49:52.040 --> 00:49:52.572 Um,
NOTE Confidence: 0.7767812

00:49:52.572 --> 00:49:54.700 instead of toxic treatment,
NOTE Confidence: 0.7767812

00:49:54.700 --> 00:49:58.120 the overall response rate was a
NOTE Confidence: 0.7767812

00:49:58.120 --> 00:50:00.400 dieta CR rate 70%.
NOTE Confidence: 0.7767812

00:50:00.400 --> 00:50:02.180 Army generation of response was
NOTE Confidence: 0.7767812

00:50:02.180 --> 00:50:04.360 not reached and let me down.
NOTE Confidence: 0.7767812

00:50:04.360 --> 00:50:06.315 Overall survival was 6.6 years
NOTE Confidence: 0.7767812

00:50:06.315 --> 00:50:08.270 treatment related mortality in this
NOTE Confidence: 0.7767812

00:50:08.329 --> 00:50:10.524 study was 8% which is the lowest
NOTE Confidence: 0.7767812

00:50:10.524 --> 00:50:12.750 reported in this patient population and

NOTE Confidence: 0.82772666

00:50:12.820 --> 00:50:14.080 this is a attribute.

NOTE Confidence: 0.82772666

00:50:14.080 --> 00:50:16.114 This has been attributed to the

NOTE Confidence: 0.82772666

00:50:16.114 --> 00:50:18.998 fact that a quarter of the patients

NOTE Confidence: 0.82772666

00:50:18.998 --> 00:50:20.938 were spared cytotoxic chemotherapy.

NOTE Confidence: 0.82772666

00:50:20.940 --> 00:50:24.210 So. What's new in PID.

NOTE Confidence: 0.82772666

00:50:24.210 --> 00:50:26.245 Recently over the past five

NOTE Confidence: 0.82772666

00:50:26.245 --> 00:50:29.196 years it has been more and more

NOTE Confidence: 0.82772666

00:50:29.196 --> 00:50:31.698 recognized than PTSD tend to be.

NOTE Confidence: 0.82772666

00:50:31.700 --> 00:50:35.860 CD 30 positive So this is a study by vision.

NOTE Confidence: 0.82772666

00:50:35.860 --> 00:50:38.164 Others that showed that out of

NOTE Confidence: 0.82772666

00:50:38.164 --> 00:50:40.242 108 patients with PTSD diagnosed

NOTE Confidence: 0.82772666

00:50:40.242 --> 00:50:43.375 between 1994 and 2011, it was 85%.

NOTE Confidence: 0.82772666

00:50:43.375 --> 00:50:46.350 Of this patient expresses CD 30 including

NOTE Confidence: 0.82772666

00:50:46.439 --> 00:50:49.585 81% of the diffuse large B cell lymphoma.

NOTE Confidence: 0.82772666

00:50:49.590 --> 00:50:52.030 This is very particular to

NOTE Confidence: 0.82772666

00:50:52.030 --> 00:50:54.470 the query after the PTLD.
NOTE Confidence: 0.82772666

00:50:54.470 --> 00:50:55.990 Because in the immunocompetent,
NOTE Confidence: 0.82772666

00:50:55.990 --> 00:50:58.270 if you started selling for my
NOTE Confidence: 0.82772666

00:50:58.338 --> 00:51:00.243 usually city third expression is
NOTE Confidence: 0.82772666

00:51:00.243 --> 00:51:02.919 probably less than 20% and not only
NOTE Confidence: 0.82772666

00:51:02.919 --> 00:51:05.217 demonstrated a high CD 30 expression.
NOTE Confidence: 0.82772666

00:51:05.220 --> 00:51:07.776 They also demonstrated that it was
NOTE Confidence: 0.82772666

00:51:07.776 --> 00:51:10.735 associated with a better outcome. So.
NOTE Confidence: 0.82772666

00:51:10.735 --> 00:51:13.760 Twice this interesting or important,
NOTE Confidence: 0.82772666

00:51:13.760 --> 00:51:16.770 we now have a drug that targets
NOTE Confidence: 0.82772666

00:51:16.770 --> 00:51:19.220 specifically city 30 brentuximab windowed
NOTE Confidence: 0.82772666

00:51:19.220 --> 00:51:22.442 and is an antibody drug conjugate
NOTE Confidence: 0.82772666

00:51:22.442 --> 00:51:25.509 that binds to the city 30 and one.
NOTE Confidence: 0.82772666

00:51:25.510 --> 00:51:27.410 Since the internalised release,
NOTE Confidence: 0.82772666

00:51:27.410 --> 00:51:29.785 monumental restarting E which is
NOTE Confidence: 0.82772666

00:51:29.785 --> 00:51:31.573 microtubule disrupting agent which

NOTE Confidence: 0.82772666

00:51:31.573 --> 00:51:33.643 end up like causing apoptosis.

NOTE Confidence: 0.82772666

00:51:33.650 --> 00:51:35.034 As we all know,

NOTE Confidence: 0.82772666

00:51:35.034 --> 00:51:37.110 grant access method Odin is now

NOTE Confidence: 0.82772666

00:51:37.193 --> 00:51:40.063 approved with various indication in

NOTE Confidence: 0.82772666

00:51:40.063 --> 00:51:42.359 Hodgkin lymphoma anaplastic large.

NOTE Confidence: 0.82772666

00:51:42.360 --> 00:51:44.940 Calling from.

NOTE Confidence: 0.82772666

00:51:44.940 --> 00:51:46.293 So in 2019,

NOTE Confidence: 0.82772666

00:51:46.293 --> 00:51:48.097 at the ASH meeting,

NOTE Confidence: 0.82772666

00:51:48.100 --> 00:51:50.760 the results of these Phase 1 two

NOTE Confidence: 0.82772666

00:51:50.760 --> 00:51:53.372 trial of Brentuximab in Jordan plus

NOTE Confidence: 0.82772666

00:51:53.372 --> 00:51:55.702 rituximab as frontline treatment for

NOTE Confidence: 0.82772666

00:51:55.702 --> 00:51:57.700 patients with immuno suppression

NOTE Confidence: 0.82772666

00:51:57.700 --> 00:52:00.175 associated lymphoma were presented and

NOTE Confidence: 0.82772666

00:52:00.175 --> 00:52:03.920 in the this was a very small study.

NOTE Confidence: 0.82772666

00:52:03.920 --> 00:52:07.360 22 patients with previously untreated

NOTE Confidence: 0.82772666

00:52:07.360 --> 00:52:08.736 immunosuppression associated.
NOTE Confidence: 0.82772666

00:52:08.740 --> 00:52:10.156 Little pretty effective disorder,
NOTE Confidence: 0.82772666

00:52:10.156 --> 00:52:11.926 including 1516 patients were PTSD
NOTE Confidence: 0.82772666

00:52:11.926 --> 00:52:13.449 post transplant clipart affective
NOTE Confidence: 0.82772666

00:52:13.449 --> 00:52:14.941 disorder patients who receive
NOTE Confidence: 0.82772666

00:52:14.941 --> 00:52:16.510 an induction were attacks.
NOTE Confidence: 0.82772666

00:52:16.510 --> 00:52:17.611 In other words,
NOTE Confidence: 0.82772666

00:52:17.611 --> 00:52:19.446 given in combination with Brent
NOTE Confidence: 0.82772666

00:52:19.446 --> 00:52:21.708 accidents and Odin and patient worry
NOTE Confidence: 0.82772666

00:52:21.708 --> 00:52:23.910 stage and according to their response,
NOTE Confidence: 0.82772666

00:52:23.910 --> 00:52:25.515 they either received more out
NOTE Confidence: 0.82772666

00:52:25.515 --> 00:52:27.639 attacks immigrant tax map in loading
NOTE Confidence: 0.82772666

00:52:27.639 --> 00:52:29.459 as consolidation and maintenance,
NOTE Confidence: 0.82772666

00:52:29.460 --> 00:52:32.064 or if they had progression of
NOTE Confidence: 0.82772666

00:52:32.064 --> 00:52:34.669 disease were removed from the study.
NOTE Confidence: 0.82772666

00:52:34.670 --> 00:52:35.906 Again, small study,

NOTE Confidence: 0.82772666

00:52:35.906 --> 00:52:37.554 very short follow-up about

NOTE Confidence: 0.82772666

00:52:37.554 --> 00:52:39.515 encouraging result with a very

NOTE Confidence: 0.82772666

00:52:39.515 --> 00:52:40.847 high overall response rate,

NOTE Confidence: 0.82772666

00:52:40.850 --> 00:52:45.150 and see a rate of 60% so.

NOTE Confidence: 0.82772666

00:52:45.150 --> 00:52:47.376 I'm I'm very excited to announce

NOTE Confidence: 0.82772666

00:52:47.376 --> 00:52:50.358 that I that we're about to open a

NOTE Confidence: 0.82772666

00:52:50.358 --> 00:52:52.494 phase two trial for this patient

NOTE Confidence: 0.82772666

00:52:52.569 --> 00:52:55.239 population here in the Yale network,

NOTE Confidence: 0.82772666

00:52:55.240 --> 00:52:58.264 and this is going to be a trial

NOTE Confidence: 0.82772666

00:52:58.264 --> 00:52:59.890 in collaboration with them.

NOTE Confidence: 0.82772666

00:52:59.890 --> 00:53:02.066 Are you clinic and with UVI so is

NOTE Confidence: 0.82772666

00:53:02.066 --> 00:53:05.331 1/2 is just trial where patients with

NOTE Confidence: 0.82772666

00:53:05.331 --> 00:53:06.921 post transplant lymphoproliferative

NOTE Confidence: 0.82772666

00:53:06.921 --> 00:53:09.793 disorder CD 20 and CD 30 positive

NOTE Confidence: 0.82772666

00:53:09.793 --> 00:53:11.528 which essentially is the vast

NOTE Confidence: 0.82772666

00:53:11.530 --> 00:53:13.590 majority of PTSD will receive
NOTE Confidence: 0.82772666

00:53:13.590 --> 00:53:15.238 an induction treatment with.
NOTE Confidence: 0.82772666

00:53:15.240 --> 00:53:17.155 Maximum burn toxin overload and
NOTE Confidence: 0.82772666

00:53:17.155 --> 00:53:19.551 and then based on the response
NOTE Confidence: 0.82772666

00:53:19.551 --> 00:53:21.969 at a pet city after induction,
NOTE Confidence: 0.82772666

00:53:21.970 --> 00:53:24.469 they will receive more of the same
NOTE Confidence: 0.82772666

00:53:24.469 --> 00:53:27.126 treatment so and there will be spared
NOTE Confidence: 0.82772666

00:53:27.126 --> 00:53:29.394 of cytotoxic treatment or will be
NOTE Confidence: 0.82772666

00:53:29.468 --> 00:53:31.476 escalated to rituximab, Pentax,
NOTE Confidence: 0.82772666

00:53:31.476 --> 00:53:33.060 Melvin Gordon, and Bendamustine,
NOTE Confidence: 0.82772666

00:53:33.060 --> 00:53:35.436 for a total of 6 cycles.
NOTE Confidence: 0.82772666

00:53:35.440 --> 00:53:37.420 Primary objective of the study.
NOTE Confidence: 0.82772666

00:53:37.420 --> 00:53:39.280 Our overall response rate complete
NOTE Confidence: 0.82772666

00:53:39.280 --> 00:53:42.050 and partial at the end of the
NOTE Confidence: 0.82772666

00:53:42.050 --> 00:53:44.150 treatment and PFS secondary objective.
NOTE Confidence: 0.82772666

00:53:44.150 --> 00:53:45.419 Intend to explore.

NOTE Confidence: 0.82772666
00:53:45.419 --> 00:53:46.688 Additional responsibilities at
NOTE Confidence: 0.82772666
00:53:46.688 --> 00:53:48.380 the end of the
NOTE Confidence: 0.779890875
00:53:48.451 --> 00:53:49.509 induction phase,
NOTE Confidence: 0.779890875
00:53:49.510 --> 00:53:51.934 which include the grant axiom of
NOTE Confidence: 0.779890875
00:53:51.934 --> 00:53:54.660 windowed in on top of rituximab,
NOTE Confidence: 0.779890875
00:53:54.660 --> 00:53:57.228 duration of response and overall survival,
NOTE Confidence: 0.779890875
00:53:57.230 --> 00:54:00.100 and we're planning to also deep dive
NOTE Confidence: 0.779890875
00:54:00.100 --> 00:54:02.380 into the frequency of infection.
NOTE Confidence: 0.779890875
00:54:02.380 --> 00:54:03.577 Peripheral sensory neuropathy,
NOTE Confidence: 0.779890875
00:54:03.577 --> 00:54:05.971 then rate doesn't craft of interaction
NOTE Confidence: 0.779890875
00:54:05.971 --> 00:54:07.958 and treatment related mortality.
NOTE Confidence: 0.779890875
00:54:07.960 --> 00:54:10.450 Exploratory studies.
NOTE Confidence: 0.779890875
00:54:10.450 --> 00:54:13.082 Are at the end to identify new biological
NOTE Confidence: 0.779890875
00:54:13.082 --> 00:54:15.368 and genetic markers that might be
NOTE Confidence: 0.779890875
00:54:15.368 --> 00:54:16.932 productive to response resistance
NOTE Confidence: 0.779890875

00:54:16.932 --> 00:54:19.269 to this therapeutic combination.
NOTE Confidence: 0.779890875

00:54:19.270 --> 00:54:22.760 So. Um?
NOTE Confidence: 0.779890875

00:54:22.760 --> 00:54:26.243 I'm going to leave you with this last slide,
NOTE Confidence: 0.779890875

00:54:26.250 --> 00:54:28.190 future strategies and these are.
NOTE Confidence: 0.779890875

00:54:28.190 --> 00:54:30.438 This is a list of the clinical trials
NOTE Confidence: 0.779890875

00:54:30.438 --> 00:54:32.481 that are currently about to recruit
NOTE Confidence: 0.779890875

00:54:32.481 --> 00:54:34.605 or recruiting for this for post
NOTE Confidence: 0.779890875

00:54:34.673 --> 00:54:37.118 transplant lymphoproliferative disorder.
NOTE Confidence: 0.779890875

00:54:37.120 --> 00:54:39.984 This top line is the study is our
NOTE Confidence: 0.779890875

00:54:39.984 --> 00:54:42.343 study that I just mentioned and
NOTE Confidence: 0.779890875

00:54:42.343 --> 00:54:45.169 we're about to open here at Yale
NOTE Confidence: 0.779890875

00:54:45.169 --> 00:54:48.353 and then the reason I just want to
NOTE Confidence: 0.779890875

00:54:48.353 --> 00:54:51.076 highlight the days a second study is.
NOTE Confidence: 0.74669033

00:54:53.090 --> 00:54:55.592 Study that follows up the PLD
NOTE Confidence: 0.74669033

00:54:55.592 --> 00:54:58.480 one trial from the German group,
NOTE Confidence: 0.74669033

00:54:58.480 --> 00:55:00.220 whether increasing where they're

NOTE Confidence: 0.74669033

00:55:00.220 --> 00:55:03.386 integrating the IPI score and the organ

NOTE Confidence: 0.74669033

00:55:03.386 --> 00:55:05.796 transplanted to further risk stratify

NOTE Confidence: 0.74669033

00:55:05.796 --> 00:55:08.206 patients after induction with rituximab

NOTE Confidence: 0.74669033

00:55:08.206 --> 00:55:10.286 and I have substituted rituximab

NOTE Confidence: 0.74669033

00:55:10.286 --> 00:55:12.980 subcu to the regular attacks enough

NOTE Confidence: 0.74669033

00:55:12.980 --> 00:55:17.100 that they used in the PTL D1 trial.

NOTE Confidence: 0.74669033

00:55:17.100 --> 00:55:19.319 Another trial that I would keep an

NOTE Confidence: 0.74669033

00:55:19.319 --> 00:55:21.823 eye on is there tax amount plus

NOTE Confidence: 0.74669033

00:55:21.823 --> 00:55:24.434 a club routine atrial that is not

NOTE Confidence: 0.74669033

00:55:24.434 --> 00:55:26.709 yet recruiting and is going to be

NOTE Confidence: 0.74669033

00:55:26.709 --> 00:55:28.756 done in Cleveland and besides this

NOTE Confidence: 0.74669033

00:55:28.756 --> 00:55:30.501 retrial which address the untreated

NOTE Confidence: 0.74669033

00:55:30.501 --> 00:55:32.149 population in the refractory setting,

NOTE Confidence: 0.74669033

00:55:32.150 --> 00:55:34.264 there are a lot of trials with

NOTE Confidence: 0.74669033

00:55:34.264 --> 00:55:36.250 the adoptive T cell treatment.

NOTE Confidence: 0.754213

00:55:37.600 --> 00:55:39.650 And with this and this,
NOTE Confidence: 0.754213

00:55:39.650 --> 00:55:42.930 is it? So thank you for your attention.
NOTE Confidence: 0.81910676

00:55:46.370 --> 00:55:48.506 Thank you, that was a wonderful
NOTE Confidence: 0.81910676

00:55:48.506 --> 00:55:50.839 talk and it's great to see that
NOTE Confidence: 0.81910676

00:55:50.839 --> 00:55:52.792 you have a trial and I guess
NOTE Confidence: 0.81910676

00:55:52.865 --> 00:55:55.030 it's opening Greninger will be.
NOTE Confidence: 0.81910676

00:55:55.030 --> 00:55:56.731 So very very well linked to the
NOTE Confidence: 0.81910676

00:55:56.731 --> 00:55:58.329 first talk we heard from Ann.
NOTE Confidence: 0.81910676

00:55:58.330 --> 00:56:00.164 Do you have any questions or comments
NOTE Confidence: 0.81910676

00:56:00.164 --> 00:56:01.629 where we're just about a time,
NOTE Confidence: 0.81910676

00:56:01.630 --> 00:56:03.916 but we might have time for one or two?
NOTE Confidence: 0.81910676

00:56:03.920 --> 00:56:04.940 If there are any.
NOTE Confidence: 0.7730721

00:56:09.260 --> 00:56:11.171 Are you seeing a lot of this
NOTE Confidence: 0.7730721

00:56:11.171 --> 00:56:12.659 in your practice right now?
NOTE Confidence: 0.7730721

00:56:12.660 --> 00:56:13.509 Princeska in Greenwich?
NOTE Confidence: 0.87719744

00:56:14.860 --> 00:56:16.630 Currently have one patient which is,

NOTE Confidence: 0.87719744

00:56:16.630 --> 00:56:18.976 which is a lot considering that

NOTE Confidence: 0.87719744

00:56:18.976 --> 00:56:21.430 I've just started two months ago.

NOTE Confidence: 0.87719744

00:56:21.430 --> 00:56:24.922 So we have we typically used to have.

NOTE Confidence: 0.87719744

00:56:24.922 --> 00:56:27.237 Colombia is a big transplant

NOTE Confidence: 0.87719744

00:56:27.237 --> 00:56:29.200 center and we we tend to.

NOTE Confidence: 0.87719744

00:56:29.200 --> 00:56:32.472 We were we were seeing a lot of

NOTE Confidence: 0.87719744

00:56:32.472 --> 00:56:35.545 these patients, but to say a lot

NOTE Confidence: 0.87719744

00:56:35.545 --> 00:56:38.450 was about 20-30 cases per year.

NOTE Confidence: 0.87719744

00:56:38.450 --> 00:56:41.320 Just to put this in context, so this is

NOTE Confidence: 0.78447115

00:56:41.320 --> 00:56:42.524 a rare disease weapon.

NOTE Confidence: 0.78447115

00:56:42.524 --> 00:56:45.149 As we grow Greenwich as a expert site,

NOTE Confidence: 0.78447115

00:56:45.150 --> 00:56:47.004 you know for these types of

NOTE Confidence: 0.78447115

00:56:47.004 --> 00:56:48.626 diseases you'll get you'll draw

NOTE Confidence: 0.78447115

00:56:48.626 --> 00:56:50.246 more and more from Manhattan,

NOTE Confidence: 0.78447115

00:56:50.250 --> 00:56:52.164 and where I'm sure there are

NOTE Confidence: 0.78447115

00:56:52.164 --> 00:56:53.440 many post transplant patients,
NOTE Confidence: 0.78447115

00:56:53.440 --> 00:56:55.040 Francine Flash has a question.
NOTE Confidence: 0.78447115

00:56:55.040 --> 00:56:56.852 She asks any role for checkpoint
NOTE Confidence: 0.78447115

00:56:56.852 --> 00:56:58.869 inhibitors in these EBV driven tumors.
NOTE Confidence: 0.862677

00:56:59.950 --> 00:57:02.606 This is a very good good question and
NOTE Confidence: 0.862677

00:57:02.606 --> 00:57:05.679 I think that due to the peculiarity
NOTE Confidence: 0.862677

00:57:05.679 --> 00:57:07.547 of these patients population,
NOTE Confidence: 0.862677

00:57:07.550 --> 00:57:09.440 which are recipients of hematopoietic
NOTE Confidence: 0.862677

00:57:09.440 --> 00:57:11.870 stem cell transplant or solid organ
NOTE Confidence: 0.862677

00:57:11.870 --> 00:57:15.860 transplant, there is a lot of.
NOTE Confidence: 0.862677

00:57:15.860 --> 00:57:18.140 We're very worried about causing
NOTE Confidence: 0.862677

00:57:18.140 --> 00:57:21.467 it'd have to be action or graft
NOTE Confidence: 0.862677

00:57:21.467 --> 00:57:24.190 versus host disease, and so I don't.
NOTE Confidence: 0.862677

00:57:24.190 --> 00:57:26.110 I'm not aware of any study
NOTE Confidence: 0.862677

00:57:26.187 --> 00:57:28.775 utilizing checkpoint inhibitors in
NOTE Confidence: 0.862677

00:57:28.775 --> 00:57:31.363 this specific patient population.

NOTE Confidence: 0.85083014

00:57:32.500 --> 00:57:35.362 OK, maybe I see a study in the making,

NOTE Confidence: 0.85083014

00:57:35.370 --> 00:57:38.120 maybe an investigator initiated trial.

NOTE Confidence: 0.85083014

00:57:38.120 --> 00:57:39.758 Well, our Francisco that was great.

NOTE Confidence: 0.85083014

00:57:39.760 --> 00:57:40.852 Thank you so much.

NOTE Confidence: 0.85083014

00:57:40.852 --> 00:57:42.217 Welcome to the group you've.

NOTE Confidence: 0.85083014

00:57:42.220 --> 00:57:43.998 It's great to have you and this

NOTE Confidence: 0.85083014

00:57:43.998 --> 00:57:45.759 will end grand rounds for today.

NOTE Confidence: 0.85083014

00:57:45.760 --> 00:57:48.040 I want to thank Renee and her team

NOTE Confidence: 0.85083014

00:57:48.040 --> 00:57:50.456 for helping get this set up and I hope

NOTE Confidence: 0.85083014

00:57:50.456 --> 00:57:52.586 everyone has a good rest of the day.

NOTE Confidence: 0.85083014

00:57:52.590 --> 00:57:55.638 Will see you see you soon.

NOTE Confidence: 0.85083014

00:57:55.640 --> 00:57:58.336 Thank you, thanks everyone.